<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Resveratrol for adults with type 2 diabetes mellitus - Jeyaraman, MM - 2020 | Cochrane Library</title> <meta content="Resveratrol for adults with type 2 diabetes mellitus - Jeyaraman, MM - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011919.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Resveratrol for adults with type 2 diabetes mellitus - Jeyaraman, MM - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011919.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011919.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Resveratrol for adults with type 2 diabetes mellitus" name="citation_title"/> <meta content="Maya M Jeyaraman" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="mjeyara@gmail.com" name="citation_author_email"/> <meta content="Nameer S H Al‐Yousif" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="Amrinder Singh Mann" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="Vernon W Dolinsky" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="Rasheda Rabbani" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="Ryan Zarychanski" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="Ahmed M Abou‐Setta" name="citation_author"/> <meta content="University of Manitoba" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD011919.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/01/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011919.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011919.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011919.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Blood Glucose [drug effects, metabolism]; Diabetes Mellitus, Type 2 [*drug therapy]; Fasting [blood]; Hypoglycemic Agents [*therapeutic use]; Randomized Controlled Trials as Topic; Resveratrol [*therapeutic use]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011919.pub2&amp;doi=10.1002/14651858.CD011919.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011919\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011919\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","fa","fr","de","zh_HANT","pl","ms","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011919.pub2",title:"Resveratrol for adults with type 2 diabetes mellitus",firstPublishedDate:"Jan 17, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011919.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011919.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011919.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011919.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011919.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011919.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011919.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011919.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011919.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011919.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13528 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011919.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-sec-0124"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-sec-0043"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-sec-0044"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-sec-0080"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-sec-0118"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/appendices#CD011919-sec-0129"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/table_n/CD011919StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/table_n/CD011919StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Resveratrol for adults with type 2 diabetes mellitus</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#CD011919-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Maya M Jeyaraman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#CD011919-cr-0003">Nameer S H Al‐Yousif</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#CD011919-cr-0004">Amrinder Singh Mann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#CD011919-cr-0005">Vernon W Dolinsky</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#CD011919-cr-0006">Rasheda Rabbani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#CD011919-cr-0007">Ryan Zarychanski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information#CD011919-cr-0008">Ahmed M Abou‐Setta</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information/en#CD011919-sec-0145">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 January 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011919.pub2">https://doi.org/10.1002/14651858.CD011919.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011919-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011919-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011919-abs-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011919-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011919-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011919-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011919-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011919-abs-0001" lang="en"> <section id="CD011919-sec-0001"> <h3 class="title" id="CD011919-sec-0001">Background</h3> <p>Type 2 diabetes mellitus (T2DM) is a chronic disorder that is characterised by insulin resistance and hyperglycaemia, which over time may give rise to vascular complications. Resveratrol is a plant‐derived nutritional supplement shown to have anti‐diabetic properties in many animal models. Less evidence is available on its safety and efficacy in the management of T2DM in humans. </p> </section> <section id="CD011919-sec-0002"> <h3 class="title" id="CD011919-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of resveratrol formulations for adults with type 2 diabetes mellitus. </p> </section> <section id="CD011919-sec-0003"> <h3 class="title" id="CD011919-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and International Pharmaceutical Abstracts, as well as the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. The date of the last search was December 2018 for all databases. No language restrictions were applied. </p> </section> <section id="CD011919-sec-0004"> <h3 class="title" id="CD011919-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) comparing effects of oral resveratrol (any dose or formulation, duration, or frequency of administration) with placebo, no treatment, other anti‐diabetic medications, or diet or exercise, in adults with a diagnosis of T2DM. </p> </section> <section id="CD011919-sec-0005"> <h3 class="title" id="CD011919-sec-0005">Data collection and analysis</h3> <p>Two review authors independently identified and included RCTs, assessed risk of bias, and extracted study‐level data. Study authors were contacted for any missing information or for clarification of reported data. We assessed studies for certainty of the evidence using the GRADE instrument. </p> </section> <section id="CD011919-sec-0006"> <h3 class="title" id="CD011919-sec-0006">Main results</h3> <p>We identified three RCTs with a total of 50 participants. Oral resveratrol not combined with other plant polyphenols was administered at 10 mg, 150 mg, or 1000 mg daily for a period ranging from four weeks to five weeks. The comparator intervention was placebo. Overall, all three included studies had low risk of bias. None of the three included studies reported long‐term, patient‐relevant outcomes such as all‐cause mortality, diabetes‐related complications, diabetes‐related mortality, health‐related quality of life, or socioeconomic effects. All three included studies reported that no adverse events were observed, indicating that no deaths occurred (very low‐quality evidence for adverse events, all‐cause mortality, and diabetes‐related mortality). Resveratrol versus placebo showed neutral effects for glycosylated haemoglobin A1c (HbA1c) levels (mean difference (MD) 0.1%, 95% confidence interval (CI) ‐0.02 to 0.2; P = 0.09; 2 studies; 31 participants; very low‐certainty evidence). Due to the short follow‐up period, HbA1c results have to be interpreted cautiously. Similarly, resveratrol versus placebo showed neutral effects for fasting blood glucose levels (MD 2 mg/dL, 95% CI ‐2 to 7; P = 0.29; 2 studies; 31 participants), and resveratrol versus placebo showed neutral effects for insulin resistance (MD ‐0.35, 95% CI ‐0.99 to 0.28; P = 0.27; 2 studies; 36 participants). We found eight ongoing RCTs with approximately 800 participants and two studies awaiting assessment, which, when published, could contribute to the findings of this review. </p> </section> <section id="CD011919-sec-0007"> <h3 class="title" id="CD011919-sec-0007">Authors' conclusions</h3> <p>Currently, research is insufficient for review authors to evaluate the safety and efficacy of resveratrol supplementation for treatment of adults with T2DM. The limited available research does not provide sufficient evidence to support any effect, beneficial or adverse, of four to five weeks of 10 mg to 1000 mg of resveratrol in adults with T2DM. Adequately powered RCTs reporting patient‐relevant outcomes with long‐term follow‐up periods are needed to further evaluate the efficacy and safety of resveratrol supplementation in the treatment of T2DM. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011919-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011919-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011919-abs-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011919-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011919-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011919-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011919-abs-0017">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011919-abs-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011919-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011919-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011919-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011919-abs-0014">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011919-abs-0006" lang="en"> <h3>Resveratrol for adults with type 2 diabetes mellitus</h3> <p><b>Review question</b> </p> <p>What are the effects of oral resveratrol supplementation compared with placebo, no treatment, anti‐diabetic medications, or diet or exercise, for the management of type 2 diabetes mellitus? </p> <p><b>Background</b> </p> <p>Type 2 diabetes mellitus is a chronic disorder characterised by increased opposition of the cells in the body to circulating insulin in the blood, possibly leading to long‐term complications in organs such as kidneys, eyes, nerves, and heart. Resveratrol is a plant‐based nutritional supplement found mainly in grapes, peanuts, blueberries, and mulberries. Many animal studies have shown it to have anti‐diabetic properties. Few human studies have been conducted so far, and it is very important that current evidence from well‐performed studies is synthesised to inform the public and researchers. </p> <p><b>Study characteristics</b> </p> <p>We identified three randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) with a total of 50 participants with type 2 diabetes. Among the included studies, the duration of resveratrol supplementation ranged from four to five weeks. Resveratrol as a capsule or Softgel was taken at 10 mg, 150 mg, or 1000 mg daily and was compared to placebo. </p> <p>This evidence is up‐to‐date as of December 2018.</p> <p><b>Key results</b> </p> <p>None of the included studies reported on important long‐term, patient‐relevant outcomes such as death from any cause, diabetes‐related death, diabetes‐related complications, health‐related quality of life, or impact on treatment costs. However, no side effects and no deaths were observed in these short‐term studies. No clear changes were observed for indicators of glucose management. We found eight ongoing studies with approximately 800 participants and two studies awaiting assessment, which, when published, could contribute to our findings. </p> <p><b>Certainty of the evidence</b> </p> <p>The overall certainty of evidence from the included studies was very low, mainly because the number of participants and the number of studies reporting the outcomes were small . Also, the duration of the studies was very short. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011919-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011919-sec-0124"></div> <h3 class="title" id="CD011919-sec-0125">Implications for practice</h3> <section id="CD011919-sec-0125"> <p>This systematic review provides limited evidence that orally administered resveratrol in Softgel or capsule form at a dose of 10 mg/d to 1000 mg/d (not combined with other plant polyphenols) for a period of four to five weeks may be safe in individuals with type 2 diabetes mellitus (T2DM) compared to placebo, but no firm conclusions on the efficacy of resveratrol could be drawn due to a dearth of studies reporting these outcomes. Although many studies using animal models have shown promising results of resveratrol in improving insulin sensitivity, insulin secretion, and blood glucose levels, there is not enough evidence yet in the scientific literature to justify supplementation of resveratrol in humans for treatment of T2DM. Lack of scientific evidence does not necessarily reflect harm, but currently, many over‐the‐counter products containing resveratrol claim a beneficial effect of resveratrol on T2DM in humans, mainly based on findings from animal studies. Humans consume resveratrol at low doses from dietary sources such as grapes, berries, and peanuts. Recommendations for higher doses of resveratrol through supplementation in the treatment of humans with T2DM should be made only on the basis of evidence from future robust clinical studies reporting patient‐relevant outcomes. </p> </section> <h3 class="title" id="CD011919-sec-0126">Implications for research</h3> <section id="CD011919-sec-0126"> <p>Based on the findings of our systematic review, it is clear that scientific evidence on the safety and efficacy of resveratrol in individuals with T2DM is very limited and is still in its infancy. We found a definite research gap in the literature investigating effects of resveratrol‐only formulations not combined with other plant polyphenols in adults with T2DM. To provide healthcare stake holders such as consumers, funders, and healthcare professionals access to best evidence on the use of resveratrol for T2DM, there is a great need to grow the available evidence base by conducting high‐quality clinical studies with large sample sizes and long‐term follow‐up periods that measure patient‐important endpoints. In addition, future studies must consider exploring socioeconomic effects as one of their study outcomes, as this may help reduce the healthcare burden that we currently face due to an alarming increase in the incidence of T2DM around the world. Although ongoing studies do not appear to address these issues (eight ongoing trials with a total of approximately 800 participants with follow‐up periods ranging from four weeks to 12 months), they still can provide valuable safety data. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011919-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011919-sec-0036"></div> <div class="table" id="CD011919-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for resveratrol plus oral anti‐diabetic drugs versus placebo plus oral anti‐diabetic drugs</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Resveratrol compared with placebo for type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> adults with type 2 diabetes mellitus<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> resveratrol + OAD<br/> <b>Comparison:</b> placebo + OAD </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo + OAD</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with resveratrol + OAD</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes‐related complications</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 4 to 5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Very low</b><sup>a</sup> </p> <p>⊕⊕⊝⊝</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events were reported, indicating that no deaths occurred</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes‐related mortality</b> </p> <p>Follow‐up: 4 to 5 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Very low</b><sup>a</sup> </p> <p>⊕⊕⊝⊝</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events were reported, indicating that no deaths occurred</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 4 to 5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>a</sup> </p> <p>⊕⊕⊝⊝</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse events were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c (%)</b> </p> <p>Follow‐up: 30 days and 5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean HbA1c in the intervention group was 0.1% higher (0.02% lower to 0.2% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b</sup> </p> <p>⊕⊕⊝⊝</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to the short follow‐up period, HbA1c results have to be interpreted cautiously</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; HbA1c: glycosylated haemoglobin A1c; OAD: oral anti‐diabetic drug(s). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level because of indirectness (insufficient time frame) and by two levels because of serious imprecision (low median sample size and small number of studies) ‐ see <a href="./appendices#CD011919-sec-0143">Appendix 14</a>.<br/> <sup>b</sup>Downgraded by one level because of indirectness (surrogate outcome and insufficient time frame) and by two levels because of serious imprecision (low median sample size and small number of studies, CI ranging between benefit and harm) ‐ see <a href="./appendices#CD011919-sec-0143">Appendix 14</a>. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011919-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011919-sec-0037"></div> <section id="CD011919-sec-0038"> <h3 class="title" id="CD011919-sec-0038">Description of the condition</h3> <p>Type 2 diabetes mellitus (T2DM) is a chronic condition characterised by insulin resistance. There is an initial early compensatory increase in insulin levels, but at a later stage, beta‐cell failure leads to decreased insulin secretion (<a href="./references#CD011919-bbs2-0076" title="Martin‐GronertMS , OzanneSE . Metabolic programming of insulin action and secretion. Diabetes, Obesity &amp; Metabolism2012;14(Suppl 3):29‐39. ">Martin‐Gronert 2012</a>). More than 366 million people worldwide are diabetic, and this number is predicted to nearly double by 2030 (<a href="./references#CD011919-bbs2-0080" title="MoserEG , MorrisAA , GargSK . Emerging diabetes therapies and technologies. Diabetes Research and Clinical Practice2012;97:16‐26. ">Moser 2012</a>). Prevalence continues to increase at an alarming rate, especially in low‐ and middle‐income countries (<a href="./references#CD011919-bbs2-0080" title="MoserEG , MorrisAA , GargSK . Emerging diabetes therapies and technologies. Diabetes Research and Clinical Practice2012;97:16‐26. ">Moser 2012</a>). T2DM is the fourth leading cause of death in high‐income nations, with a two‐fold excess risk of mortality and a two‐ to four‐fold increase in the risk of cardiovascular disease (<a href="./references#CD011919-bbs2-0078" title="McKinlayJ , MarceauL . US public health and the 21st century: diabetes mellitus. Lancet2000;356:757‐61. ">McKinlay 2000</a>). </p> <p>Macrovascular complications of T2DM include coronary artery disease, peripheral arterial disease, and stroke; microvascular complications include diabetic nephropathy and retinopathy (<a href="./references#CD011919-bbs2-0063" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalTP , WetterslevJ . Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD008143.pub3] ">Hemmingsen 2013</a>). Management of T2DM has traditionally been approached in a step‐wise manner, starting with 'lifestyle' modifications, exercise, and, if still uncontrolled, pharmacotherapy with oral anti‐diabetic drugs and insulin (<a href="./references#CD011919-bbs2-0046" title="BirdSR , HawleyJA . Exercise and type 2 diabetes: new prescription for an old problem. Maturitas2012;72:311‐6. ">Bird 2012</a>; <a href="./references#CD011919-bbs2-0057" title="El‐KaissiS , SherbeeniS . Pharmacological management of type 2 diabetes mellitus: an update. Current Diabetes Reviews2011;7:392‐405. ">El‐Kaissi 2011</a>). Although studies have shown that improved long‐term glycaemic control in people with T2DM, measured by glycosylated haemoglobin A1c (HbA1c), leads to a reduction in both microvascular and macrovascular complications (<a href="./references#CD011919-bbs2-0080" title="MoserEG , MorrisAA , GargSK . Emerging diabetes therapies and technologies. Diabetes Research and Clinical Practice2012;97:16‐26. ">Moser 2012</a>), a recent systematic review and meta‐analysis concluded that evidence is insufficient to show the influence of targeting intensive glycaemic control on macrovascular complications (<a href="./references#CD011919-bbs2-0063" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalTP , WetterslevJ . Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD008143.pub3] ">Hemmingsen 2013</a>). However, targeting intensive glycaemic control has been shown to possibly reduce the risk of microvascular complications (<a href="./references#CD011919-bbs2-0063" title="HemmingsenB , LundSS , GluudC , VaagA , AlmdalTP , WetterslevJ . Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD008143.pub3] ">Hemmingsen 2013</a>). </p> <p>Anti‐diabetic drugs are not taken without adverse effects and complications. Hypoglycaemia is a major concern among individuals taking these agents, as they may directly cause or contribute to hypoglycaemia (<a href="./references#CD011919-bbs2-0058" title="GerminoFW . Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. Clinical Therapeutics2011;33:1868‐82. ">Germino 2011</a>). </p> </section> <section id="CD011919-sec-0039"> <h3 class="title" id="CD011919-sec-0039">Description of the intervention</h3> <p>Resveratrol is a natural polyphenolic anti‐oxidant synthesised by several plant species, including grapes, peanuts, mulberries, and blueberries (<a href="./references#CD011919-bbs2-0053" title="BurnsJ , YokotaT , AshiharaH , LeanME , CrozierA . Plant foods and herbal sources of resveratrol. Journal of Agricultural and Food Chemistry2002;50:3337‐40. ">Burns 2002</a>; <a href="./references#CD011919-bbs2-0088" title="RimandoAM , KaltW , MageeJB , DeweyJ , BallingtonJR . Resveratrol, pterostilbene, and piceatannol in vaccinium berries. Journal of Agricultural and Food Chemistry2004;52:4713‐9. ">Rimando 2004</a>), and it is available in tablet form. Although resveratrol has therapeutic properties, its pharmacokinetic properties, reflected by its poor bioavailability due to rapid metabolisation, pose a major challenge to its use. To circumvent this issue, novel drug delivery systems to improve its stability and increase its bioavailability have been formulated (<a href="./references#CD011919-bbs2-0085" title="PangeniR , SahniJK , AliJ , SharmaS , BabootaS . Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opinion on Drug Delivery2014;11(8):1285‐98. ">Pangeni 2014</a>). Studies have reported the use of micro‐formulations and nano‐formulations for encapsulation of resveratrol, such as polymeric nanoparticles, liposomes, lipospheres, solid lipid nanoparticles, polymeric microspheres, cyclodextrins, calcium or zinc pectinate beads, and yeast cell carriers (<a href="./references#CD011919-bbs2-0081" title="NevesAR , LucioM , LimaJL , ReisS . Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug‐delivery, and membrane interactions. Current Medicinal Chemistry2012;19(11):1663‐81. ">Neves 2012</a>). However, use of these novel delivery systems generally has not been attempted in humans. </p> <section id="CD011919-sec-0040"> <h4 class="title">Adverse effects of the intervention</h4> <p>A small number of studies have reported on the safety and tolerability of resveratrol in humans (<a href="./references#CD011919-bbs2-0042" title="AlmeidaL , Vaz‐da‐SilvaM , FalcaoA , SoaresE , CostaR , LoureiroAI , et al. Pharmacokinetic and safety profile of trans‐resveratrol in a rising multiple‐dose study in healthy volunteers. Molecular Nutrition &amp; Food Research2009;53(Suppl 1):S7‐15. ">Almeida 2009</a>; <a href="./references#CD011919-bbs2-0047" title="BoocockDJ , FaustGE , PatelKR , SchinasAM , BrownVA , DucharmeMP , et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology, Biomarkers &amp; Prevention2007;16:1246‐52. ">Boocock 2007</a>; <a href="./references#CD011919-bbs2-0052" title="BrownVA , PatelKR , ViskadurakiM , CrowellJA , PerloffM , BoothTD , et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin‐like growth factor axis. Cancer Research2010;70:9003‐11. ">Brown 2010</a>; <a href="./references#CD011919-bbs2-0054" title="ChowHH , GarlandLL , HsuCH , ViningDR , ChewWM , MillerJA , et al. Resveratrol modulates drug‐ and carcinogen‐metabolizing enzymes in a healthy volunteer study. Cancer Prevention Research (Philadelphia, Pa.)2010;3:1168‐75. ">Chow 2010</a>; <a href="./references#CD011919-bbs2-0072" title="LaPorteC , VoducN , ZhangG , SeguinI , TardiffD , SinghalN , et al. Steady‐state pharmacokinetics and tolerability of trans‐resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clinical Pharmacokinetics2010;49:449‐54. ">La Porte 2010</a>). <a href="./references#CD011919-bbs2-0052" title="BrownVA , PatelKR , ViskadurakiM , CrowellJA , PerloffM , BoothTD , et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin‐like growth factor axis. Cancer Research2010;70:9003‐11. ">Brown 2010</a> reported mild gastrointestinal adverse effects at higher doses of 2.5 g and 5 g, and recommended that safe doses should perhaps not exceed 1 g; however, no hypoglycaemia was reported. In addition, these mild adverse effects could not directly be attributed to resveratrol due to lack of a control group in the study design. </p> </section> </section> <section id="CD011919-sec-0041"> <h3 class="title" id="CD011919-sec-0041">How the intervention might work</h3> <p>Numerous animal studies have demonstrated the beneficial effects of resveratrol in managing diabetes through various mechanisms such as preservation of beta‐cells (<a href="./references#CD011919-bbs2-0060" title="HansenJB , ArkhammarPO , BodvarsdottirTB , WahlP . Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Current Medicinal Chemistry2004;11:1595‐615. ">Hansen 2004</a>; <a href="./references#CD011919-bbs2-0084" title="PalsamyP , SubramanianS . Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta‐cell dysfunction in streptozotocin‐nicotinamide‐induced diabetic rats. Journal of Cellular Physiology2010;224:423‐32. ">Palsamy 2010</a>), improvement in the action of insulin and blood insulin concentrations (<a href="./references#CD011919-bbs2-0083" title="PalsamyP , SubramanianS . Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin‐nicotinamide‐induced diabetic rats. Chemico‐biological Interactions2009;179:356‐62. ">Palsamy 2009</a>), and improvement in insulin sensitivity (<a href="./references#CD011919-bbs2-0044" title="BaurJA , PearsonKJ , PriceNL , JamiesonHA , LerinC , KalraA , et al. Resveratrol improves health and survival of mice on a high‐calorie diet. Nature2006;444:337‐42. ">Baur 2006</a>; <a href="./references#CD011919-bbs2-0073" title="LagougeM , ArgmannC , Gerhart‐HinesZ , MezianeH , LerinC , DaussinF , et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC‐1alpha. Cell2006;127:1109‐22. ">Lagouge 2006</a>). Anti‐cytotoxic and anti‐oxidant effects of resveratrol have been proposed to play an important role in protecting the pancreas in diabetes. Studies have also revealed diminished levels of HbA1c in response to administration of resveratrol in diabetic rats, which is a reflection of a prolonged reduction in hyperglycaemia (<a href="./references#CD011919-bbs2-0082" title="PalsamyP , SubramanianS . Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin‐nicotinamide induced experimental diabetic rats. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2008;62:598‐605. ">Palsamy 2008</a>; <a href="./references#CD011919-bbs2-0084" title="PalsamyP , SubramanianS . Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta‐cell dysfunction in streptozotocin‐nicotinamide‐induced diabetic rats. Journal of Cellular Physiology2010;224:423‐32. ">Palsamy 2010</a>). </p> <p>A few clinical studies have shown resveratrol to improve insulin sensitivity and HbA1c levels in persons with T2DM (<a href="./references#CD011919-bbs2-0045" title="BhattJK , ThomasS , NanjanMJ . Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research (New York, NY)2012;32:537‐41. ">Bhatt 2012</a>; <a href="./references#CD011919-bbs2-0051" title="BrasnyoP , MolnarGA , MohasM , MarkoL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyo 2011</a>). Based on these preliminary findings, it is possible that resveratrol could lead to clinical improvement in insulin sensitivity and glycaemic control, and to a decrease in diabetic complications. </p> </section> <section id="CD011919-sec-0042"> <h3 class="title" id="CD011919-sec-0042">Why it is important to do this review</h3> <p>Type 2 diabetes is a serious chronic disease that presents a huge healthcare and economic burden. A few clinical studies have been published on the efficacy of resveratrol in the management of T2DM (<a href="./references#CD011919-bbs2-0045" title="BhattJK , ThomasS , NanjanMJ . Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research (New York, NY)2012;32:537‐41. ">Bhatt 2012</a>; <a href="./references#CD011919-bbs2-0051" title="BrasnyoP , MolnarGA , MohasM , MarkoL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyo 2011</a>). Primary studies have indicated that resveratrol represents a potential treatment strategy for T2DM; therefore it is important to synthesise available evidence to explore its beneficial effects as well as any associated adverse effects. Previous systematic reviews have evaluated and reported the effects of resveratrol on cardio‐metabolic biomarkers in individuals with or without diabetes, and in individuals already undergoing pharmaceutical interventions for T2DM (<a href="./references#CD011919-bbs2-0062" title="HausenblasHA , SchouldaJA , SmoligaJM . Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus ‐ systematic review and meta‐analysis. Molecular Nutrition &amp; Food Research2015;59(1):147‐59. ">Hausenblas 2015</a>; <a href="./references#CD011919-bbs2-0075" title="LiuK , ZhouR , WangB , MiMT . Effect of resveratrol on glucose control and insulin sensitivity: a meta‐analysis of 11 randomized controlled trials. American Journal of Clinical Nutrition2014;99(6):1510‐9. ">Liu 2014</a>; <a href="./references#CD011919-bbs2-0095" title="ZhuX , WuC , QiuS , YuanX , LiL . Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta‐analysis. Nutrition and Metabolism2017;14:60. ">Zhu 2017</a>). However, these systematic reviews did not assess the effects of resveratrol on important, clinically relevant outcomes such as mortality, diabetes‐related complications, and health‐related quality of life. Although surrogate outcomes may provide useful information, it is very important to assess clinically relevant outcomes that are directly meaningful to individuals living with diabetes, as this may help not only to decrease the burden of the disease but also to highlight potential research gaps that researchers need to address. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011919-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011919-sec-0043"></div> <p>To assess the efficacy and safety of resveratrol for adults with type 2 diabetes mellitus.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011919-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011919-sec-0044"></div> <section id="CD011919-sec-0045"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011919-sec-0046"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> </section> <section id="CD011919-sec-0047"> <h4 class="title">Types of participants</h4> <p>Adults (18 years or older) with diagnosis of T2DM. In the case of mixed studies, at least 80% of participants had to be adult persons with T2DM. </p> <section id="CD011919-sec-0048"> <h5 class="title">Diagnostic criteria for diabetes mellitus</h5> <p>To be consistent with changes over the years in the classification and diagnostic criteria for diabetes mellitus, we included studies with diagnoses established using the standard criteria valid at the time the study commenced (e.g. <a href="./references#CD011919-bbs2-0040" title="The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, the American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care1999;22(Suppl 1):S5‐19. ">ADA 1999</a>; <a href="./references#CD011919-bbs2-0041" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2008. Diabetes Care2008;31(Suppl 1):S12‐54. ">ADA 2008</a>; <a href="./references#CD011919-bbs2-0092" title="AlbertiKM , ZimmetPZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine1998;15:539‐53. ">WHO 1998</a>). If diagnostic criteria were not described, we used the study authors' definition of diabetes mellitus. </p> </section> </section> <section id="CD011919-sec-0049"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons.</p> <section id="CD011919-sec-0050"> <h5 class="title">Intervention</h5> <p> <ul id="CD011919-list-0001"> <li> <p>Oral resveratrol (any dose, formulation, duration, or frequency of administration).</p> </li> </ul> </p> </section> <section id="CD011919-sec-0051"> <h5 class="title">Comparator</h5> <p> <ul id="CD011919-list-0002"> <li> <p>Placebo.</p> </li> <li> <p>Anti‐diabetic medications (oral anti‐diabetic drugs, herbal supplements, nutritional preparations, insulin). </p> </li> <li> <p>Diet and/or exercise.</p> </li> <li> <p>No treatment.</p> </li> </ul> </p> <p>Concomitant interventions had to be the same in intervention and comparator groups to establish fair comparisons. </p> </section> </section> <section id="CD011919-sec-0052"> <h4 class="title">Types of outcome measures</h4> <section id="CD011919-sec-0053"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011919-list-0003"> <li> <p>All‐cause mortality</p> </li> <li> <p>Diabetes‐related complications</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> <section id="CD011919-sec-0054"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011919-list-0004"> <li> <p>Diabetes‐related mortality</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>HbA1c</p> </li> <li> <p>Fasting blood glucose</p> </li> <li> <p>Insulin sensitivity</p> </li> <li> <p>Socioeconomic effects</p> </li> </ul> </p> <section id="CD011919-sec-0055"> <h6 class="title">Method of outcome measurement</h6> <p> <ul id="CD011919-list-0005"> <li> <p>All‐cause mortality: defined as number of deaths due to any cause in the study population</p> </li> <li> <p>Diabetes‐related complications: macrovascular complications defined as stroke, angina, myocardial infarction (heart attack), leg and foot pain; microvascular complications defined as retinopathy (vision loss or blindness), nephropathy (renal failure), cardiomyopathy (heart failure), neuropathy (diabetic foot) </p> </li> <li> <p>Diabetes‐related mortality: defined as death from myocardial infarction, stroke, peripheral vascular disease, renal disease, hyperglycaemia, hypoglycaemia, sudden death </p> </li> <li> <p>Adverse events: any adverse events, serious adverse events, and all other reported adverse events </p> </li> <li> <p>HbA1c: measured as percentage or as mmol/mol</p> </li> <li> <p>Fasting blood glucose: any measurement of fasting blood glucose</p> </li> <li> <p>Insulin sensitivity: any measurement of homeostasis model assessment of insulin resistance (HOMA‐IR) </p> </li> <li> <p>Health‐related quality of life: measured with any validated instrument</p> </li> <li> <p>Socioeconomic effects: defined as the economic and social position of the individual in relation to others, as determined by education, income, and/or occupation </p> </li> </ul> </p> </section> <section id="CD011919-sec-0056"> <h6 class="title">Timing of outcome measurement</h6> <p> <ul id="CD011919-list-0006"> <li> <p>All outcomes measured at any time after participants were randomised to intervention/comparator groups </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD011919-sec-0057"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011919-sec-0058"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database to the specified date and placed no restrictions on the language of publication. </p> <p> <ul id="CD011919-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO) (December 2018; Issue 11 of 12). </p> </li> <li> <p>MEDLINE (Ovid SP MEDLINE ALL 1946 to present) (12 April 2018).</p> </li> <li> <p>Embase (Ovid SP 1974 to 3 December 2018) (12 April 2018).</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCO (12 April 2018). </p> </li> <li> <p>International Pharmaceutical Abstracts (12 April 2018).</p> </li> <li> <p><a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> (12 April 2018). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>) (12 April 2018). </p> </li> </ul> </p> <p>For detailed search strategies, see <a href="./appendices#CD011919-sec-0130">Appendix 1</a>. </p> </section> <section id="CD011919-sec-0059"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible studies or ancillary publications by searching the reference lists of retrieved included studies, systematic reviews, meta‐analyses, and health technology assessment reports. We performed a citation search for key studies in Scopus and Web of Science. In addition, we contacted authors of included studies to obtain additional information on the retrieved studies and to establish whether we have missed further studies. We defined grey literature as records detected in ClinicalTrials.gov or on the WHO ICTRP. </p> </section> </section> <section id="CD011919-sec-0060"> <h3 class="title" id="CD011919-sec-0060">Data collection and analysis</h3> <section id="CD011919-sec-0061"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MJ, ASM) independently screened the title, the abstract, or both, of every record we retrieved in the literature searches, to determine which studies we should assess further. We obtained the full text of all potentially relevant records. We resolved disagreements through consensus or by recourse to a third review author (AMAS). If we could not resolve a disagreement, we categorised the study as one of the <a href="./references#CD011919-bbs1-0003" title="">Studies awaiting classification</a> and contacted the study authors for clarification. We present an adapted PRISMA flow diagram to show the process of study selection (<a href="./references#CD011919-bbs2-0074" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine2009;6(7):1‐28. ">Liberati 2009</a>). We listed all articles excluded after full‐text assessment in the <a href="./references#CD011919-sec-0150" title="">Characteristics of excluded studies</a> table and provided the reasons for exclusion. </p> </section> <section id="CD011919-sec-0062"> <h4 class="title">Data extraction and management</h4> <p>For studies that fulfilled the inclusion criteria, two review authors (MJ, NA) independently extracted key participant and intervention characteristics. We reported data on efficacy outcomes and adverse events using standardised data extraction sheets from the Cochrane Metabolic &amp; Endocrine Disorders (CMED) Group. We resolved disagreements by discussion or, if required, by consultation with a third review author (AMAS) (for details, see <a href="./references#CD011919-sec-0149" title="">Characteristics of included studies</a>; <a href="#CD011919-tbl-0002">Table 1</a>; <a href="./appendices#CD011919-sec-0131">Appendix 2</a>; <a href="./appendices#CD011919-sec-0132">Appendix 3</a>; <a href="./appendices#CD011919-sec-0133">Appendix 4</a>; <a href="./appendices#CD011919-sec-0134">Appendix 5</a>; <a href="./appendices#CD011919-sec-0135">Appendix 6</a>; <a href="./appendices#CD011919-sec-0136">Appendix 7</a>; <a href="./appendices#CD011919-sec-0137">Appendix 8</a>; <a href="./appendices#CD011919-sec-0138">Appendix 9</a>; <a href="./appendices#CD011919-sec-0139">Appendix 10</a>; <a href="./appendices#CD011919-sec-0140">Appendix 11</a>; <a href="./appendices#CD011919-sec-0141">Appendix 12</a>; <a href="./appendices#CD011919-sec-0140">Appendix 11</a>; <a href="./appendices#CD011919-sec-0141">Appendix 12</a>; <a href="./appendices#CD011919-sec-0142">Appendix 13</a>; <a href="./appendices#CD011919-sec-0143">Appendix 14</a>). </p> <div class="table" id="CD011919-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of study populations</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID<br/> (study design)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing study<br/> (N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing study<br/> (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a> </p> <p>(cross‐over RCT, 30‐day washout period)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: trans‐resveratrol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"We estimated 14 subjects were required to achieve 80% power, with an assumed treatment difference of 1.4 mg/kg fat‐free mass/min after 30 days and an assumed SD of 1.7 mg/kg fat‐free mass/min for a hyperinsulinaemic clamp. A dropout of 20% was taken into account, so 17 subjects were recruited" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>30 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a> </p> <p>(cross‐over RCT, 5‐week washout period)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: resveratrol capsule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A sample size of 14 subjects would have 80% power (at alpha = 0.05) to detect a 50% difference in the postprandial AUC for plasma total GLP‐1, which was the primary endpoint" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>5 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011919-bbs2-0051" title="BrasnyoP , MolnarGA , MohasM , MarkoL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyo 2011</a> </p> <p>(parallel RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: resveratrol capsule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Grand total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All comparators</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions and comparators</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>81</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>81</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>— denotes not reported.</p> <p><sup>a</sup>Cross‐over study: each participant received both placebo and resveratrol; total number of participants was 50.<br/> AUC: area under the curve. </p> <p>C: comparator, GLP‐1: glucagon‐like peptide‐1, I: intervention, RCT: randomised controlled trial. </p> </div> </div> <p>We provided information including study identifier for potentially relevant ongoing trials in the <a href="./references#CD011919-sec-0152" title="">Characteristics of ongoing studies</a> table and in <a href="./appendices#CD011919-sec-0136">Appendix 7</a>, 'Matrix of study endpoints (publications and trial documents)'. We tried to find the protocol for each included trial and reported in <a href="./appendices#CD011919-sec-0136">Appendix 7</a> primary, secondary and other outcomes in comparison with data in the publications. </p> <p>We emailed all authors of included studies to ask whether they would be willing to answer questions regarding their studies. We have presented the results of this survey in <a href="./appendices#CD011919-sec-0142">Appendix 13</a>. We thereafter sought relevant missing information on the study from the primary author(s) of the article, if required. </p> <section id="CD011919-sec-0063"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary study, we maximised the information yield by collating all available data and used the most complete dataset aggregated across all known publications.<br/> <br/> We listed duplicate publications, companion documents, multiple reports of a primary study, and trial documents of included studies (such as trial registry information) as secondary references under the study identifier (ID) of the included study. Furthermore, we listed duplicate publications, companion documents, multiple reports of a study, and trial documents of excluded studies (such as trial registry information) as secondary references under the study ID of the excluded study. </p> </section> <section id="CD011919-sec-0064"> <h5 class="title">Data from clinical trials registers</h5> <p>If data from included studies were available as study results in clinical trials registers, such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> or similar sources, we made full use of this information and extracted the data. If there was also a full publication of the study, we collated and critically appraised all available data. If an included study was marked as a completed study in a clinical trial register but no additional information (study results, publication, or both) was available, we added this study to the <a href="./references#CD011919-sec-0151" title="">Characteristics of studies awaiting classification</a> table. </p> </section> </section> <section id="CD011919-sec-0065"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MJ, NA) independently assessed the risk of bias for each included study. We resolved disagreements by consensus, or by consultation with a third review author (AMAS). In cases of disagreement, we consulted the remainder of the review author team and made a judgement based on consensus. If adequate information was unavailable from the publication, study protocols, or other sources, we contacted the study authors for more detail to request missing data on 'Risk of bias' items. </p> <p>We used the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD011919-bbs2-0067" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ2011; Vol. 343:d5928. ">Higgins 2011a</a>; <a href="./references#CD011919-bbs2-0069" title="HigginsJP , AltmanDG , SterneJA , editors(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), and we assigned assessments of low, high, or unclear risk of bias (for details, see <a href="./appendices#CD011919-sec-0131">Appendix 2</a>; <a href="./appendices#CD011919-sec-0132">Appendix 3</a>). We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> according to the criteria and associated categorisations contained therein (<a href="./references#CD011919-bbs2-0069" title="HigginsJP , AltmanDG , SterneJA , editors(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). </p> <section id="CD011919-sec-0066"> <h5 class="title">Summary assessment of risk of bias</h5> <p>We presented a 'Risk of bias' graph and a 'Risk of bias' summary figure.</p> <p>We distinguished between self‐reported, investigator‐assessed, and adjudicated outcome measures. </p> <p>We considered the following endpoints as self‐reported.</p> <p> <ul id="CD011919-list-0008"> <li> <p>Adverse events.</p> </li> <li> <p>Health‐related quality of life.</p> </li> </ul> </p> <p>We considered the following endpoints as investigator‐assessed.</p> <p> <ul id="CD011919-list-0009"> <li> <p>Adverse events.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Diabetes‐related complications.</p> </li> <li> <p>Diabetes‐related mortality.</p> </li> <li> <p>HbA1c.</p> </li> <li> <p>Fasting blood glucose.</p> </li> <li> <p>Insulin sensitivity.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> <section id="CD011919-sec-0067"> <h6 class="title">Risk of bias for a study across outcomes</h6> <p>Some 'Risk of bias' domains, such as selection bias (sequence generation and allocation sequence concealment), affect the risk of bias across all outcome measures in a study. In case of high risk of selection bias, we marked all endpoints investigated in the associated study as high risk. Otherwise, we did not perform a summary assessment of risk of bias across all outcomes for a study. </p> </section> <section id="CD011919-sec-0068"> <h6 class="title">Risk of bias for an outcome within a study and across domains</h6> <p>We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both study‐level entries and outcome‐specific entries). We considered low risk of bias to denote low risk of bias for all key domains, unclear risk to denote unclear risk of bias for one or more key domains, and high risk to denote high risk of bias for one or more key domains. </p> </section> <section id="CD011919-sec-0069"> <h6 class="title">Risk of bias for an outcome across studies and across domains</h6> <p>These are the main summary assessments that we incorporated into our judgements about the certainty of evidence in the 'Summary of findings' tables. We defined outcomes as at low risk of bias when most information came from studies at low risk of bias, at unclear risk of bias when most information came from studies at low or unclear risk of bias, and at high risk of bias when a sufficient proportion of information came from studies at high risk of bias. </p> </section> </section> </section> <section id="CD011919-sec-0070"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two included studies were available for a comparison of a given outcome, we tried to express dichotomous data as a risk ratio (RR) or an odds ratio (OR) with 95% confidence interval (CI). For continuous outcomes measured on the same scale (e.g. fasting blood glucose in mg/dL), we estimated the intervention effect using the mean difference (MD) with 95% CI. For continuous outcomes that measured the same underlying concept (e.g. health‐related quality of life) but used different measurement scales, we planned to calculate the standardised mean difference (SMD). We planned to express time‐to‐event data as a hazard ratio (HR) with 95% CI. </p> </section> <section id="CD011919-sec-0071"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred, such as cross‐over studies, cluster‐randomised trials, and multiple observations for the same outcome. If outcomes were presented at several time points, we included only data from the longest follow‐up period. For cross‐over studies, we included only data obtained before the cross‐over unless the intraclass correlation (ICC) coefficient was reported. We planned to include data from cluster‐randomised trials only if the intracluster correlation coefficient was reported (<a href="./references#CD011919-bbs2-0068" title="HigginsJP , DeeksJJ , AltmanDG , editor(s) . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.cochrane.org. ">Higgins 2011b</a>). </p> </section> <section id="CD011919-sec-0072"> <h4 class="title">Dealing with missing data</h4> <p>If possible, we obtained missing data from the authors of included studies. We carefully evaluated important numerical data such as number screened, randomly assigned participants, and intention‐to‐treat (ITT) and as‐treated and per‐protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals), and we critically appraised issues concerning missing data and imputation methods (e.g. last observation carried forward (LOCF)). </p> </section> <section id="CD011919-sec-0073"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we did not report study results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1 (<a href="./references#CD011919-bbs2-0056" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). In view of the low power of this test, we considered the I² statistic, which quantifies inconsistency across studies, to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD011919-bbs2-0064" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539‐58. ">Higgins 2002</a>; <a href="./references#CD011919-bbs2-0065" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analysis. BMJ2003;327:557‐60. ">Higgins 2003</a>). </p> <p>Had we found heterogeneity, we would have attempted to determine possible reasons for this by examining individual study and subgroup characteristics. </p> </section> <section id="CD011919-sec-0074"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 or more studies that investigated a particular outcome, we used funnel plots to assess small‐study effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to study size, poor methodological design (and hence bias of small studies), and publication bias (<a href="./references#CD011919-bbs2-0091" title="SterneJA , EggerM , MoherD , BoutronI , editor(s) . Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Sterne 2017</a>). Therefore we interpreted the results carefully (<a href="./references#CD011919-bbs2-0061" title="HartB , LundhA , BeroL . Effect of reporting bias on meta‐analyses of drug trials: reanalysis of meta‐analyses. BMJ2012;344:d7202. [DOI: 10.1136/bmj.d7202] ">Hart 2012</a>; <a href="./references#CD011919-bbs2-0090" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). </p> </section> <section id="CD011919-sec-0075"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake (or display) a meta‐analysis only if we judged participants, interventions, comparisons, and outcomes to be sufficiently similar to ensure an answer that was clinically meaningful. Unless good evidence showed homogeneous effects across studies of different methodological quality, we primarily summarised low risk of bias data using a random‐effects model (<a href="./references#CD011919-bbs2-0094" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration for the whole distribution of effects and planned to present a prediction interval (<a href="./references#CD011919-bbs2-0048" title="BorensteinM , HigginsJP , HedgesLV , RothsteinHR . Basics of meta‐analysis: I² is not an absolute measure of heterogeneity. Research Synthesis Methods2017;8(1):5‐18. ">Borenstein 2017a</a>; <a href="./references#CD011919-bbs2-0049" title="BorensteinM . Prediction intervals. www.meta‐analysis.com/prediction (accessed 3 July 2017). ">Borenstein 2017b</a>; <a href="./references#CD011919-bbs2-0066" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society. Series A (Statistics in Society)2009;172(1):137‐59. ">Higgins 2009</a>). A prediction interval requires at least three studies to be calculated and specifies a predicted range for the true treatment effect in an individual study (<a href="./references#CD011919-bbs2-0087" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta‐analyses. BMJ2011;342:d549. ">Riley 2011</a>). For rare events such as event rates below 1%, we planned to use the Peto odds ratio method, provided there was no substantial imbalance between intervention and comparator group sizes, and intervention effects were not exceptionally large. In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011919-bbs2-0056" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD011919-sec-0076"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to potentially introduce clinical heterogeneity, and we planned to carry out the following subgroup analyses with investigation of interactions (<a href="./references#CD011919-bbs2-0043" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. [PUBMED: 12543843] ">Altman 2003</a>). </p> <p> <ul id="CD011919-list-0010"> <li> <p>Sex (male/female).</p> </li> <li> <p>Participants with or without comorbidities (participants with heart attack, stroke, peripheral vascular disease). </p> </li> <li> <p>Treatment effect by co‐intervention (insulin, oral anti‐diabetic drugs).</p> </li> <li> <p>Treatment dosage (low dose (&lt; 250 mg/d), moderate dose (250 to 1000 mg/d), high dose (&gt; 1000 mg/d)). </p> </li> <li> <p>Treatment duration (short (&lt; 6 months), medium (6 months to 2 years), long (&gt; 2 years)).</p> </li> <li> <p>Treatment formulation (pure resveratrol, timed release, other additives).</p> </li> <li> <p>Different comparators (e.g. placebo, no additional treatment, oral hypoglycaemic medications, insulin). </p> </li> </ul> </p> </section> <section id="CD011919-sec-0077"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting analysis to the following. </p> <p> <ul id="CD011919-list-0011"> <li> <p>Published studies.</p> </li> <li> <p>Very long (&gt; 1 year) or large studies to establish the extent to which they dominate the results (&lt; 100 participants vs ≥ 100 participants). </p> </li> <li> <p>Use of the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry vs other), country. </p> </li> <li> <p>Effect of risk of bias, as specified in the <a href="#CD011919-sec-0065">Assessment of risk of bias in included studies</a> section. </p> </li> </ul> </p> <p>We planned to test the robustness of results by repeating analysis using different measures of effect size (i.e. RR, OR, etc) and different statistical models (fixed‐effect and random‐effects models). </p> <section id="CD011919-sec-0078"> <h5 class="title">Certainty of the evidence</h5> <p>We presented the overall certainty of evidence for each outcome specified below, according to the GRADE approach, which took into account issues related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and to external validity (directness of results)<i>.</i> Two review authors (MJ, AMAS) independently rated the certainty of evidence for each outcome. </p> <p>We included <a href="./appendices#CD011919-sec-0143">Appendix 14</a> entitled 'Checklist to aid consistency and reproducibility of GRADE assessments', to help with standardisation of the 'Summary of findings' tables (<a href="./references#CD011919-bbs2-0079" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. ">Meader 2014</a>). Alternatively, we planned to use the GRADEpro Guideline Development Tool (GDT) software and would have presented evidence profile tables as an appendix (<a href="./references#CD011919-bbs2-0059" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Version accessed 1 October 2018. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEproGDT 2015</a>). We presented results for outcomes as described in the <a href="https://archie.cochrane.org/sections/documents/view?version=z1808031458212484512759462179235%26format=REVMAN#CRIT_OUTCOMES" target="_blank">Types of outcome measures</a> section. When meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the certainty of evidence by using footnotes, and we made comments to aid the reader's understanding of the Cochrane Review when necessary. </p> <section id="CD011919-sec-0079"> <h6 class="title">'Summary of findings' table</h6> <p>We presented a summary of evidence in <a href="./full#CD011919-tbl-0001">summary of findings Table for the main comparison</a>. This provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants, and studies addressing each important outcome, and a rating of overall confidence in effect estimates for each outcome. We created the 'Summary of findings' table based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011919-bbs2-0089" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>), using Review Manager (RevMan 5.3) table editor (<a href="./references#CD011919-bbs2-0086" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>The intervention presented in the 'Summary of findings' table was oral resveratrol, and the comparator was placebo. </p> <p>We reported the following outcomes, listed according to priority.</p> <p> <ul id="CD011919-list-0012"> <li> <p>Diabetes‐related complications.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Diabetes‐related mortality.</p> </li> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Adverse events.</p> </li> <li> <p>HbA1c.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011919-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011919-sec-0080"></div> <section id="CD011919-sec-0081"> <h3 class="title">Description of studies</h3> <p>For a detailed description of studies, see the <a href="./references#CD011919-sec-0149" title="">Characteristics of included studies</a>, <a href="./references#CD011919-sec-0150" title="">Characteristics of excluded studies,</a> and <a href="./references#CD011919-sec-0152" title="">Characteristics of ongoing studies</a> sections. </p> <section id="CD011919-sec-0082"> <h4 class="title">Results of the search</h4> <p>Our comprehensive literature searches conducted until December 2018 initially identified 832 records. After de‐duplication, we included 762 abstracts for initial title/abstract screening. After title/abstract screening, we excluded 702 records that clearly were not relevant to our review question. Full texts and records were retrieved for the rest of the 60 records. After full‐text screening, we excluded 26 studies and gave the reasons for exclusion in the <a href="#CD011919-sec-0093">Excluded studies</a> section. Ten of the 60 full‐text articles/records could not be included for reasons of incomparability (due to a combination of a rather unspecified mixture of oral anti‐diabetic agents with/without resveratrol ‐ <a href="./references#CD011919-bbs2-0004" title="ACTRN12610000565044 . Pilot clinical trial for treatment of diabetic foot ulcers with dietary nano‐formulated phytochemicals. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335696 (first received 09 July 2010). BashmakovYK , Assaad‐KhalilSH , Abou SeifM , UdumyanR , MegallaaM , RohomaKH , et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinology2014;2014:1‐8. ">Bashmakov 2014</a>; <a href="./references#CD011919-bbs2-0005" title="BhattJK , NanjanMJ . Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. International Research Journal of Pharmacy2013;4(8):245‐9. BhattJK , ThomasS , NanjanMJ . Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research (New York, N.Y.)2012;32(7):537‐41. CTRI/2011/05/001731 . Evaluation of resveratrol as a dietary supplement in type 2 diabetes mellitus. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=2998&amp;EncHid=&amp;modid=&amp;compid=%27,%272998det%27 (first received 16 April 2010). ">Bhatt 2013</a>; <a href="./references#CD011919-bbs2-0006" title="BoS , GambinoR , PonzoV , CioffiI , GoitreI , EvangelistaA , et al. Effects of resveratrol on bone health in type 2 diabetic patients. a double‐blind randomized‐controlled trial. Nutrition and Diabetes2018;8(1):51. BoS , PonzoV , CicconeG , EvangelistaA , SabaF , GoitreI , et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. a randomized, double blind, placebo‐controlled trial. Pharmacological Research2016;111:896‐905. BoS , PonzoV , EvangelistaA , CicconeG , GoitreI , SabaF , et al. Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double‐blind randomized controlled trial. Acta Diabetologica2017;54(5):499‐507. BoS , TogliattoG , GambinoR , PonzoV , LombardoG , RosatoR , et al. Impact of sirtuin‐1 expression on H3K56 acetylation and oxidative stress: a double‐blind randomized controlled trial with resveratrol supplementation. Acta diabetologica2018;55(4):331‐40. NCT02244879 . Effects of resveratrol on inflammation in type 2 diabetic patients. clinicaltrials.gov/show/NCT02244879 (first received 19 September 2014). ">Bo 2018</a>; <a href="./references#CD011919-bbs2-0009" title="GohKP , LeeHY , LauDP , SupaatW , ChanYH , KohAF . Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. International Journal of Sport Nutrition and Exercise Metabolism2014;24:2‐13. NCT01677611 . Effects of resveratrol in patients with type 2 diabetes (RED). clinicaltrials.gov/show/NCT01677611 (first received 3 September 2012). ">Goh 2014</a>; <a href="./references#CD011919-bbs2-0010" title="ImamuraH , YamaguchiT , NagayamaD , SaikiA , ShiraiK , TatsunoI . Resveratrol ameliorates arterial stiffness assessed by cardio‐ankle vascular index in patients with type 2 diabetes mellitus. International Heart Journal2017;58(4):577‐83. ">Imamura 2017</a>; <a href="./references#CD011919-bbs2-0013" title="IRCT2015080223336N2 . The effect of resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) inflammatory factors of patients with type 2 diabetes. en.irct.ir/trial/19923 (first received 25 July 2015). KhodabandehlooH , SeyyedebrahimiS , EsfahaniEN , RaziF , MeshkaniR . Resveratrol supplementation decreases blood glucose without changing the circulating CD14(+)CD16(+) monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Nutrition Research (New York, N.Y.)2018;54:40‐51. ">Khodabandehloo 2018</a>; <a href="./references#CD011919-bbs2-0016" title="IRCT201111198129N1 . Effect of resveratrol in controlling blood glucose in type 2 diabetic patients. en.irct.ir/trial/8549 (first received 19 September 2011). MovahedA , NabipourI , LiebenXL , ThandapillySJ , YuL , KalantarhormoziM , et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence‐based Complementary and Alternative Medicine2013;2013:1‐8. MovahedA , NabipourI , LouisXL , JosephS , YuL , NetticadanT . Short‐term resveratrol supplementation improves metabolic profile in type 2 diabetes. Diabetes Technology &amp; Therapeutics2014;16:A46‐A47. ">Movahed 2014</a>; <a href="./references#CD011919-bbs2-0027" title="IRCT2016100716876N2 . Resveratrol's effects in diabetic nephropathy. https://en.irct.ir/trial/15666 (first received 25 November 2016). NCT02704494 . Resveratrol's effects in diabetic nephropathy. clinicaltrials.gov/show/NCT02704494 (first received 10 March 2016). SattarinezhadA , RoozbehJ , YeganehBS , OmraniGR , ShamsM . Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double‐blind placebo‐controlled clinical trial. Diabetes and Metabolism2018;S1262‐3636(18):30114‐9. ">Sattarinezhad 2018</a>; <a href="./references#CD011919-bbs2-0028" title="IRCT2015072523336N1 . The effects of resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) oxidative stress factors of type 2 diabetic patients. https://en.irct.ir/trial/19922 (first received 19 August 2015). SeyyedebrahimiS , KhodabandehlooH , Nasli EsfahaniE , MeshkaniR . Correction to: the effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled clinical trial. Acta Diabetologica 2018 Jun 16 [Epub ahead of print]. [DOI: 10.1007/s00592‐018‐1160‐9] SeyyedebrahimiS , KhodabandehlooH , Nasli EsfahaniE , MeshkaniR . The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled clinical trial. Acta Diabetologica2018;55(4):341‐53. ">Seyyedebrahimi 2018</a>; <a href="./references#CD011919-bbs2-0011" title="IRCT2015012420765N1 . Impact of resveratrol supplementation on periodontal indices, antioxidant status, inflammatory markers and blood sugar in periodontal patients with type 2 diabetes mellitus. en.irct.ir/trial/18354 (first received 29 March 2015). JavidAZ , HormoznejadR , YousefimaneshHA , ZakerkishM , Haghighi‐ZadehMH , DehghanP , et al. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytotherapy Research2017;31(1):108‐14. ">Javid 2017</a>). </p> <p>Thirteen studies (18 records) met the review inclusion criteria. Eight of the 13 included studies were ongoing clinical trials (<a href="./references#CD011919-bbs2-0032" title="CTRI/2017/04/008384 . A study to check whether addition of resveratrol is beneficial and safe in patients with diabetes, dyslipidemia and hypertension (who are already on standard therapy). www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=11073 (first received 20 April 2017). ">CTRI/2017/04/008384</a>; <a href="./references#CD011919-bbs2-0033" title="IRCT201411112394N14 . Effects of resveratrol on mood and cognition in patients with type 2 diabetes. en.irct.ir/trial/2084?revision=2084 (first received 18 August 2015). ">IRCT201411112394N14</a>; <a href="./references#CD011919-bbs2-0034" title="IRCT201601022394N19 . Effect of resveratrol on serum irisin and adiponectin in patients with type 2 diabetes. en.irct.ir/trial/2085 (first received 24 July 2016). ">IRCT201601022394N19</a>; <a href="./references#CD011919-bbs2-0035" title="IRCT20171118037528N1 . Effect of resveratrol on vascular function. en.irct.ir/trial/27734 (first received 29 December 2017). ">IRCT20171118037528N1</a>; <a href="./references#CD011919-bbs2-0036" title="NCT01158417 . Resveratrol in type2 diabetes and obesity. clinicaltrials.gov/show/NCT01158417 (first received 8 July 2010). ">NCT01158417</a>; <a href="./references#CD011919-bbs2-0037" title="NCT01881347 . Effects of resveratrol on endothelial function in type 2 diabetes mellitus. clinicaltrials.gov/show/NCT01881347 (first received 19 June 2013). ">NCT01881347</a>; <a href="./references#CD011919-bbs2-0038" title="NCT02549924 . Effect of administration of resveratrol on glycemic variability in individuals with type 2 diabetes mellitus. clinicaltrials.gov/show/NCT02549924 (first received 15 September 2015). ">NCT02549924</a>; <a href="./references#CD011919-bbs2-0039" title="SLCTR/2018/019 . Effects of delta‐tocotrienol, resveratrol and vitamin D supplementation mixture on biochemical markers in diabetic patients. slctr.lk/trials/1304 (first received 21 June 2018). ">SLCTR/2018/019</a>). Two of the 13 included studies are awaiting classification (<a href="./references#CD011919-bbs2-0030" title="ACTRN12614000891628 . Dose response evaluation of resveratrol supplementation on cerebrovascular function, mood and cognitive performance in type 2 diabetes mellitus (T2DM). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366701 (first received 12 August 2014). WongRH , NealonRS , ScholeyA , HowePR . Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus. Nutrition, Metabolism, and Cardiovascular Diseases2016;26(5):393‐9. WongRH , RaederstorffD , HowePR . Acute resveratrol consumption improves neurovascular coupling capacity in adults with type 2 diabetes mellitus. Nutrients2016;8(7):425. ">ACTRN12614000891628</a>; <a href="./references#CD011919-bbs2-0031" title="VergesB , BrindisiMC , BouilletB , CrevisyE , BuffierP , Baillot‐RudoniS , et al. Is long‐acting resveratrol effective on the residual dyslipidemia in statin‐treated type 2 diabetic patients?. Atherosclerosis2014;235(2014):e192. ">Verges 2014</a>). Finally, we included three clinical studies (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). All three included studies were published in English. The PRISMA study flow diagram (<a href="#CD011919-fig-0001">Figure 1</a>) depicts the study selection process. </p> <div class="figure" id="CD011919-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011919-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011919-sec-0083"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included studies is presented elsewhere (see <a href="./references#CD011919-sec-0149" title="">Characteristics of included studies</a>; <a href="./appendices#CD011919-sec-0133">Appendix 4</a>; <a href="./appendices#CD011919-sec-0134">Appendix 5</a>; <a href="./appendices#CD011919-sec-0135">Appendix 6</a>; <a href="./appendices#CD011919-sec-0136">Appendix 7</a>; <a href="./appendices#CD011919-sec-0138">Appendix 9</a>; and <a href="#CD011919-tbl-0002">Table 1</a>). The following is a succinct overview. </p> <section id="CD011919-sec-0084"> <h5 class="title">Source of data</h5> <p>Most data from included studies presented in this review were obtained from published full‐text articles. We made an attempt to contact the study authors of all included studies to obtain any unpublished data on relevant outcomes and to request clarification of methodological issues (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). We received responses from authors of two studies (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). We obtained study characteristics for ongoing clinical trials from clinical trials registers. We also made an attempt to contact authors of ongoing trials to obtain unpublished data if available. However, we did not receive a response from these authors to date. </p> </section> <section id="CD011919-sec-0085"> <h5 class="title">Comparisons</h5> <p>We planned to include the following six different comparisons for this review.</p> <p> <ul id="CD011919-list-0013"> <li> <p>Resveratrol vs placebo.</p> </li> <li> <p>Resveratrol vs anti‐diabetic medications.</p> </li> <li> <p>Resveratrol vs diet.</p> </li> <li> <p>Resveratrol vs exercise.</p> </li> <li> <p>Resveratrol vs diet and exercise.</p> </li> <li> <p>Resveratrol vs no treatment.</p> </li> </ul> </p> <p>All three included published studies compared the effect of resveratrol treatment versus placebo in participants with T2DM. </p> </section> <section id="CD011919-sec-0086"> <h5 class="title">Overview of study populations</h5> <p>A total of 50 participants with T2DM were included in the three included studies of this review. The total number of participants randomised to the resveratrol treatment group was 41, and the total number of participants randomised to the placebo group was 40 (due to two studies with a cross‐over design, these numbers appear greater than the actual numbers of participants). The percentage of participants finishing the study in the intervention and comparator groups was 100%. Individual sample size in the included studies of this review ranged from 14 to 19 participants. </p> </section> <section id="CD011919-sec-0087"> <h5 class="title">Study design</h5> <p>All included studies were randomised controlled studies; two had a cross‐over study design (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>), and one had a parallel design (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). All studies were single‐centre studies. All studies used placebo as comparison. In terms of blinding, all three studies were double‐blinded and were published between 2011 and 2016. Study duration ranged from four weeks to five weeks. One study reported a run‐in period of four weeks (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). None of the studies reported a post‐intervention follow‐up period. Also, none of the included studies was terminated before the planned study end. </p> </section> <section id="CD011919-sec-0088"> <h5 class="title">Settings</h5> <p>The three included studies in this review were conducted in different countries: Australia (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>), Hungary (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>), and The Netherlands (<a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). For other details, see <a href="./references#CD011919-sec-0149" title="">Characteristics of included studies</a>. Funding sources for the included studies were as follows: two studies were funded by research grants from national funding agencies (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>), and one study reported that investigators did not receive any funding (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). </p> </section> <section id="CD011919-sec-0089"> <h5 class="title">Participants</h5> <p>A total of 50 participants with a diagnosis of T2DM were included in this review. All included participants were adults with a mean age ranging between 53 and 67 years. In two studies, all participants were males (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>), and in one study, 27% of participants were females (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>). The mean duration of T2DM in study participants ranged from five years to seven years. <a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a> did not report the duration of diabetes. Two studies included participants from high‐income countries (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>), and one study included participants from a middle‐income country (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). All included studies recruited participants who were white. Mean HbA1c levels at baseline ranged from 6.4% to 7.6%. Mean baseline body mass index (BMI) ranged from 27.7 kg/m² to 30.5 kg/m². One study did not report baseline BMI (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). One study reported that there were no comorbidities among study participants (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>), whereas another study did not report any details on comorbidities (<a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). One study reported comorbidities such as Ischaemic heart disease, peripheral arterial disease, hypercholesterolaemia, angina pectoris, diabetic neuropathy, and diabetic nephropathy (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). Among the three included studies, one study included participants who were on an anti‐diabetic medication or diet (<a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>); most study participants were on oral hypoglycaemic agents (sulphonylurea derivatives and/or metformin), and some were on diet alone (6%). Another study included participants who were treated by diet alone (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>). In the third study, participants were treated with angiotensin‐converting enzyme inhibitors or angiotensin II receptor blocker medication (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). The inclusion and exclusion criteria for the included studies are outlined in the <a href="./references#CD011919-sec-0149" title="">Characteristics of included studies</a> section. </p> </section> <section id="CD011919-sec-0090"> <h5 class="title">Diagnosis</h5> <p>All participants in the included studies had T2DM. Two studies confirmed the diagnosis against WHO diagnostic criteria (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>). The third study relied on third party diagnosis of T2DM and did not report a reference to standard diagnostic criteria for T2DM (<a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). </p> </section> <section id="CD011919-sec-0091"> <h5 class="title">Interventions</h5> <p>All included studies reported using oral resveratrol in capsule or tablet form not combined with other plant polyphenols. Two studies used trans‐resveratrol (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). The daily dose of resveratrol varied widely between the included studies: 10 mg/d (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>), 150 mg/d (<a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>), and 1000 mg/d (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>). All included studies reported use of placebo as a comparator. Placebo ingredients were reported by two studies as microcrystalline cellulose (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>). One study did not report the ingredient for the placebo (<a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). Another study reported using matching placebo (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). The duration of the intervention ranged from 4 weeks in <a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a> and <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a> to 5 weeks in <a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>. </p> </section> <section id="CD011919-sec-0092"> <h5 class="title">Outcomes</h5> <p>Two studies explicitly reported primary and secondary outcome measures in their publications and trial documents (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). Primary outcomes reported in these studies were insulin sensitivity, plasma total glucagon‐peptide 1 (GLP‐1) concentrations, and insulin resistance/sensitivity. For one study, we were unable to find a trial protocol (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). We contacted study authors but did not receive a response. For a summary of all outcome measures reported in each of the studies included in this review, see <a href="./appendices#CD011919-sec-0136">Appendix 7</a>. </p> <p>None of the included studies reported on diabetes‐related complications, health‐related quality of life, or socioeconomic effects. Because no adverse events were observed, we concluded that there were no diabetes‐related deaths or deaths from any cause. However, due to short follow‐up, no study was powered to investigate mortality. </p> </section> </section> <section id="CD011919-sec-0093"> <h4 class="title">Excluded studies</h4> <p>After thorough full‐text screening, we excluded 26 studies (<a href="./references#CD011919-bbs2-0004" title="ACTRN12610000565044 . Pilot clinical trial for treatment of diabetic foot ulcers with dietary nano‐formulated phytochemicals. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335696 (first received 09 July 2010). BashmakovYK , Assaad‐KhalilSH , Abou SeifM , UdumyanR , MegallaaM , RohomaKH , et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinology2014;2014:1‐8. ">Bashmakov 2014</a>; <a href="./references#CD011919-bbs2-0005" title="BhattJK , NanjanMJ . Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. International Research Journal of Pharmacy2013;4(8):245‐9. BhattJK , ThomasS , NanjanMJ . Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research (New York, N.Y.)2012;32(7):537‐41. CTRI/2011/05/001731 . Evaluation of resveratrol as a dietary supplement in type 2 diabetes mellitus. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=2998&amp;EncHid=&amp;modid=&amp;compid=%27,%272998det%27 (first received 16 April 2010). ">Bhatt 2013</a>; <a href="./references#CD011919-bbs2-0006" title="BoS , GambinoR , PonzoV , CioffiI , GoitreI , EvangelistaA , et al. Effects of resveratrol on bone health in type 2 diabetic patients. a double‐blind randomized‐controlled trial. Nutrition and Diabetes2018;8(1):51. BoS , PonzoV , CicconeG , EvangelistaA , SabaF , GoitreI , et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. a randomized, double blind, placebo‐controlled trial. Pharmacological Research2016;111:896‐905. BoS , PonzoV , EvangelistaA , CicconeG , GoitreI , SabaF , et al. Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double‐blind randomized controlled trial. Acta Diabetologica2017;54(5):499‐507. BoS , TogliattoG , GambinoR , PonzoV , LombardoG , RosatoR , et al. Impact of sirtuin‐1 expression on H3K56 acetylation and oxidative stress: a double‐blind randomized controlled trial with resveratrol supplementation. Acta diabetologica2018;55(4):331‐40. NCT02244879 . Effects of resveratrol on inflammation in type 2 diabetic patients. clinicaltrials.gov/show/NCT02244879 (first received 19 September 2014). ">Bo 2018</a>; <a href="./references#CD011919-bbs2-0007" title="ElliottPJ , WalpoleSM , MorelliL , LambertPD , LunsmannW , WestphalCH , et al. Resveratrol/SRT501. Sirtuin SIRT1 activator treatment of type 2 diabetes. Drugs of the Future2009;34:291‐5. ">Elliott 2009</a>; <a href="./references#CD011919-bbs2-0008" title="FujitakaK , OtaniH , JoF , JoH , NomuraE , IwasakiM , et al. Modified resveratrol longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutrition Research (New York, N.Y.)2011;31:842‐7. ">Fujitaka 2011</a>; <a href="./references#CD011919-bbs2-0009" title="GohKP , LeeHY , LauDP , SupaatW , ChanYH , KohAF . Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. International Journal of Sport Nutrition and Exercise Metabolism2014;24:2‐13. NCT01677611 . Effects of resveratrol in patients with type 2 diabetes (RED). clinicaltrials.gov/show/NCT01677611 (first received 3 September 2012). ">Goh 2014</a>; <a href="./references#CD011919-bbs2-0010" title="ImamuraH , YamaguchiT , NagayamaD , SaikiA , ShiraiK , TatsunoI . Resveratrol ameliorates arterial stiffness assessed by cardio‐ankle vascular index in patients with type 2 diabetes mellitus. International Heart Journal2017;58(4):577‐83. ">Imamura 2017</a>; <a href="./references#CD011919-bbs2-0011" title="IRCT2015012420765N1 . Impact of resveratrol supplementation on periodontal indices, antioxidant status, inflammatory markers and blood sugar in periodontal patients with type 2 diabetes mellitus. en.irct.ir/trial/18354 (first received 29 March 2015). JavidAZ , HormoznejadR , YousefimaneshHA , ZakerkishM , Haghighi‐ZadehMH , DehghanP , et al. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytotherapy Research2017;31(1):108‐14. ">Javid 2017</a>; <a href="./references#CD011919-bbs2-0012" title="KhazaeiS , FirouzeiMS , AfghariP , KhazaeiM . Resveratrol may improve osseointegration of dental implants in type 2 diabetes mellitus patients. Journal of Research in Medical Sciences2014;19:81. ">Khazaei 2014</a>; <a href="./references#CD011919-bbs2-0013" title="IRCT2015080223336N2 . The effect of resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) inflammatory factors of patients with type 2 diabetes. en.irct.ir/trial/19923 (first received 25 July 2015). KhodabandehlooH , SeyyedebrahimiS , EsfahaniEN , RaziF , MeshkaniR . Resveratrol supplementation decreases blood glucose without changing the circulating CD14(+)CD16(+) monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Nutrition Research (New York, N.Y.)2018;54:40‐51. ">Khodabandehloo 2018</a>; <a href="./references#CD011919-bbs2-0014" title="KjaerTN , PoulsenMM , OrnstrupMJ , JorgensenJ , RichelsenB , PedersenSB . The metabolic and anti‐inflammatory effects of long‐term resveratrol intake; a randomised clinical trial. Diabetologia2014;57:S306‐7. ">Kjaer 2014</a>; <a href="./references#CD011919-bbs2-0015" title="Mendez‐Del VillarM , Gonzalez‐OrtizM , Martinez‐AbundisE , Perez‐RubioKG , Lizarraga‐ValdezR . Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metabolic Syndrome and Related Disorders2014;12:497‐501. ">Mendez‐Del 2014</a>; <a href="./references#CD011919-bbs2-0016" title="IRCT201111198129N1 . Effect of resveratrol in controlling blood glucose in type 2 diabetic patients. en.irct.ir/trial/8549 (first received 19 September 2011). MovahedA , NabipourI , LiebenXL , ThandapillySJ , YuL , KalantarhormoziM , et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence‐based Complementary and Alternative Medicine2013;2013:1‐8. MovahedA , NabipourI , LouisXL , JosephS , YuL , NetticadanT . Short‐term resveratrol supplementation improves metabolic profile in type 2 diabetes. Diabetes Technology &amp; Therapeutics2014;16:A46‐A47. ">Movahed 2014</a>; <a href="./references#CD011919-bbs2-0017" title="NCT00937222 . Effects of peanut and peanut butter consumption on blood lipids and glycemic control in adults with type 2 diabetes. clinicaltrials.gov/show/NCT00937222 (first received 10 July 2009). ">NCT00937222</a>; <a href="./references#CD011919-bbs2-0018" title="NCT01038089 . Pilot study of the effects of resveratrol on endothelial function in subjects with type 2 diabetes mellitus. clinicaltrials.gov/show/NCT01038089 (first received 23 December 2009). ">NCT01038089</a>; <a href="./references#CD011919-bbs2-0019" title="NCT01150955 . Potential beneficial effects of resveratrol. clinicaltrials.gov/show/NCT01150955 (first received 25 June 2010). ">NCT01150955</a>; <a href="./references#CD011919-bbs2-0020" title="NCT01375959 . Pilot study of resveratrol in older adults with impaired glucose tolerance. clinicaltrials.gov/show/NCT01375959 (first received 20 June 2011). ">NCT01375959</a>; <a href="./references#CD011919-bbs2-0021" title="NCT01714102 . Resveratrol and the metabolic syndrome. clinicaltrials.gov/show/NCT01714102 (first received 25 October 2012). ">NCT01714102</a>; <a href="./references#CD011919-bbs2-0022" title="NCT01997762 . Can resveratrol improve insulin sensitivity and preserve beta cell function following gestational diabetes?. clinicaltrials.gov/show/NCT01997762 (first received 28 November 2013). ">NCT01997762</a>; <a href="./references#CD011919-bbs2-0023" title="NCT02129595 . Resveratrol and first‐degree relatives of type 2 diabetic patients. clinicaltrials.gov/show/NCT02129595 (first received 2 May 2014). ">NCT02129595</a>; <a href="./references#CD011919-bbs2-0024" title="NCT02216552 . Resveratrol for the treatment of non alcoholic fatty liver disease and insulin resistance in overweight adolescents. clinicaltrials.gov/show/NCT02216552 (first received 15 August 2014). ">NCT02216552</a>; <a href="./references#CD011919-bbs2-0025" title="NCT02219906 . Resveratrol in metabolic syndrome. clinicaltrials.gov/show/NCT02219906 (first received 19 August 2014). ">NCT02219906</a>; <a href="./references#CD011919-bbs2-0026" title="NCT02565979 . Long‐term resveratrol and metabolism. clinicaltrials.gov/show/NCT02565979 (first received 1 October 2015). ">NCT02565979</a>; <a href="./references#CD011919-bbs2-0027" title="IRCT2016100716876N2 . Resveratrol's effects in diabetic nephropathy. https://en.irct.ir/trial/15666 (first received 25 November 2016). NCT02704494 . Resveratrol's effects in diabetic nephropathy. clinicaltrials.gov/show/NCT02704494 (first received 10 March 2016). SattarinezhadA , RoozbehJ , YeganehBS , OmraniGR , ShamsM . Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double‐blind placebo‐controlled clinical trial. Diabetes and Metabolism2018;S1262‐3636(18):30114‐9. ">Sattarinezhad 2018</a>; <a href="./references#CD011919-bbs2-0028" title="IRCT2015072523336N1 . The effects of resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) oxidative stress factors of type 2 diabetic patients. https://en.irct.ir/trial/19922 (first received 19 August 2015). SeyyedebrahimiS , KhodabandehlooH , Nasli EsfahaniE , MeshkaniR . Correction to: the effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled clinical trial. Acta Diabetologica 2018 Jun 16 [Epub ahead of print]. [DOI: 10.1007/s00592‐018‐1160‐9] SeyyedebrahimiS , KhodabandehlooH , Nasli EsfahaniE , MeshkaniR . The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled clinical trial. Acta Diabetologica2018;55(4):341‐53. ">Seyyedebrahimi 2018</a>; <a href="./references#CD011919-bbs2-0029" title="Tomé‐CarneiroJ , GonzálvezM , LarrosaM , Yáñez‐GascónMJ , García‐AlmagroFJ , Ruiz‐RosJA , et al. One‐year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. American Journal of Cardiology2012;110:356‐63. ">Tomé‐Carneiro 2012</a>). The main reasons for exclusion were incomparability of interventions and controls because a combination of a rather unspecified mixture of oral anti‐diabetic agents was used with/without resveratrol (<a href="./references#CD011919-bbs2-0004" title="ACTRN12610000565044 . Pilot clinical trial for treatment of diabetic foot ulcers with dietary nano‐formulated phytochemicals. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335696 (first received 09 July 2010). BashmakovYK , Assaad‐KhalilSH , Abou SeifM , UdumyanR , MegallaaM , RohomaKH , et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinology2014;2014:1‐8. ">Bashmakov 2014</a>; <a href="./references#CD011919-bbs2-0005" title="BhattJK , NanjanMJ . Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. International Research Journal of Pharmacy2013;4(8):245‐9. BhattJK , ThomasS , NanjanMJ . Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research (New York, N.Y.)2012;32(7):537‐41. CTRI/2011/05/001731 . Evaluation of resveratrol as a dietary supplement in type 2 diabetes mellitus. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=2998&amp;EncHid=&amp;modid=&amp;compid=%27,%272998det%27 (first received 16 April 2010). ">Bhatt 2013</a>; <a href="./references#CD011919-bbs2-0006" title="BoS , GambinoR , PonzoV , CioffiI , GoitreI , EvangelistaA , et al. Effects of resveratrol on bone health in type 2 diabetic patients. a double‐blind randomized‐controlled trial. Nutrition and Diabetes2018;8(1):51. BoS , PonzoV , CicconeG , EvangelistaA , SabaF , GoitreI , et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. a randomized, double blind, placebo‐controlled trial. Pharmacological Research2016;111:896‐905. BoS , PonzoV , EvangelistaA , CicconeG , GoitreI , SabaF , et al. Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double‐blind randomized controlled trial. Acta Diabetologica2017;54(5):499‐507. BoS , TogliattoG , GambinoR , PonzoV , LombardoG , RosatoR , et al. Impact of sirtuin‐1 expression on H3K56 acetylation and oxidative stress: a double‐blind randomized controlled trial with resveratrol supplementation. Acta diabetologica2018;55(4):331‐40. NCT02244879 . Effects of resveratrol on inflammation in type 2 diabetic patients. clinicaltrials.gov/show/NCT02244879 (first received 19 September 2014). ">Bo 2018</a>; <a href="./references#CD011919-bbs2-0009" title="GohKP , LeeHY , LauDP , SupaatW , ChanYH , KohAF . Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. International Journal of Sport Nutrition and Exercise Metabolism2014;24:2‐13. NCT01677611 . Effects of resveratrol in patients with type 2 diabetes (RED). clinicaltrials.gov/show/NCT01677611 (first received 3 September 2012). ">Goh 2014</a>; <a href="./references#CD011919-bbs2-0010" title="ImamuraH , YamaguchiT , NagayamaD , SaikiA , ShiraiK , TatsunoI . Resveratrol ameliorates arterial stiffness assessed by cardio‐ankle vascular index in patients with type 2 diabetes mellitus. International Heart Journal2017;58(4):577‐83. ">Imamura 2017</a>; <a href="./references#CD011919-bbs2-0011" title="IRCT2015012420765N1 . Impact of resveratrol supplementation on periodontal indices, antioxidant status, inflammatory markers and blood sugar in periodontal patients with type 2 diabetes mellitus. en.irct.ir/trial/18354 (first received 29 March 2015). JavidAZ , HormoznejadR , YousefimaneshHA , ZakerkishM , Haghighi‐ZadehMH , DehghanP , et al. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytotherapy Research2017;31(1):108‐14. ">Javid 2017</a>; <a href="./references#CD011919-bbs2-0013" title="IRCT2015080223336N2 . The effect of resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) inflammatory factors of patients with type 2 diabetes. en.irct.ir/trial/19923 (first received 25 July 2015). KhodabandehlooH , SeyyedebrahimiS , EsfahaniEN , RaziF , MeshkaniR . Resveratrol supplementation decreases blood glucose without changing the circulating CD14(+)CD16(+) monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Nutrition Research (New York, N.Y.)2018;54:40‐51. ">Khodabandehloo 2018</a>; <a href="./references#CD011919-bbs2-0016" title="IRCT201111198129N1 . Effect of resveratrol in controlling blood glucose in type 2 diabetic patients. en.irct.ir/trial/8549 (first received 19 September 2011). MovahedA , NabipourI , LiebenXL , ThandapillySJ , YuL , KalantarhormoziM , et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence‐based Complementary and Alternative Medicine2013;2013:1‐8. MovahedA , NabipourI , LouisXL , JosephS , YuL , NetticadanT . Short‐term resveratrol supplementation improves metabolic profile in type 2 diabetes. Diabetes Technology &amp; Therapeutics2014;16:A46‐A47. ">Movahed 2014</a>; <a href="./references#CD011919-bbs2-0027" title="IRCT2016100716876N2 . Resveratrol's effects in diabetic nephropathy. https://en.irct.ir/trial/15666 (first received 25 November 2016). NCT02704494 . Resveratrol's effects in diabetic nephropathy. clinicaltrials.gov/show/NCT02704494 (first received 10 March 2016). SattarinezhadA , RoozbehJ , YeganehBS , OmraniGR , ShamsM . Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double‐blind placebo‐controlled clinical trial. Diabetes and Metabolism2018;S1262‐3636(18):30114‐9. ">Sattarinezhad 2018</a>; <a href="./references#CD011919-bbs2-0028" title="IRCT2015072523336N1 . The effects of resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) oxidative stress factors of type 2 diabetic patients. https://en.irct.ir/trial/19922 (first received 19 August 2015). SeyyedebrahimiS , KhodabandehlooH , Nasli EsfahaniE , MeshkaniR . Correction to: the effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled clinical trial. Acta Diabetologica 2018 Jun 16 [Epub ahead of print]. [DOI: 10.1007/s00592‐018‐1160‐9] SeyyedebrahimiS , KhodabandehlooH , Nasli EsfahaniE , MeshkaniR . The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled clinical trial. Acta Diabetologica2018;55(4):341‐53. ">Seyyedebrahimi 2018</a>), or because study participants did not have T2DM (see <a href="./references#CD011919-sec-0150" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD011919-sec-0094"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, all three included studies were adjudicated to be at low risk of bias (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). For details on risk of bias of the included studies, see <a href="./references#CD011919-sec-0149" title="">Characteristics of included studies</a>. For an overview of review authors' judgements about each risk of bias item for individual studies and across all studies, see <a href="#CD011919-fig-0002">Figure 2</a> and <a href="#CD011919-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011919-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not measured in some studies)." data-id="CD011919-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not measured in some studies). </p> </div> </div> </div> <div class="figure" id="CD011919-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not measure that particular outcome)." data-id="CD011919-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not measure that particular outcome). </p> </div> </div> </div> <section id="CD011919-sec-0095"> <h4 class="title">Allocation</h4> <p>With regard to random sequence generation, we judged all studies to be at low risk of bias. None of the three included studies provided information on allocation concealment; studies were assessed as having unclear risk of bias for this selection bias domain. </p> </section> <section id="CD011919-sec-0096"> <h4 class="title">Blinding</h4> <p>With the exception of adverse events in <a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>, we judged all other outcome to be at low risk of performance and detection bias. </p> </section> <section id="CD011919-sec-0097"> <h4 class="title">Incomplete outcome data</h4> <p>We judged all reported outcome measures for the three included studies to be at low risk of attrition bias. </p> </section> <section id="CD011919-sec-0098"> <h4 class="title">Selective reporting</h4> <p>Two included studies had study documents in the clinical trial registry (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>); outcomes reported in the trial documents matched outcomes reported in the results section of the publication and were extractable. Thus, we judged both studies to be at low risk of reporting bias. One study did not have trial documents in the clinical trial registry (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>), and we assigned this study unclear risk of reporting bias. </p> </section> <section id="CD011919-sec-0099"> <h4 class="title">Other potential sources of bias</h4> <p>Two of the included studies were of cross‐over design (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). Because T2DM is a stable condition over short time periods and because an adequate washout period was reported, we attributed low risk of bias in this domain. In addition, we found no evidence for other potential sources of bias in any of the included studies. </p> </section> </section> <section id="CD011919-sec-0100"> <h3 class="title" id="CD011919-sec-0100">Effects of interventions</h3> <p>See: <a href="./full#CD011919-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings for resveratrol plus oral anti‐diabetic drugs versus placebo plus oral anti‐diabetic drugs</a> </p> <section id="CD011919-sec-0101"> <h4 class="title">Baseline characteristics</h4> <p>For details of baseline characteristics, see <a href="./appendices#CD011919-sec-0134">Appendix 5</a> and <a href="./appendices#CD011919-sec-0135">Appendix 6</a>. </p> </section> <section id="CD011919-sec-0102"> <h4 class="title">Resveratrol versus placebo</h4> <section id="CD011919-sec-0103"> <h5 class="title">Primary outcomes</h5> <section id="CD011919-sec-0104"> <h6 class="title">All‐cause mortality</h6> <p>No study was powered to investigate all‐cause mortality (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>; <a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>). However, all study authors reported that no adverse events were observed, indicating that no deaths occurred (very low‐certainty evidence). </p> </section> <section id="CD011919-sec-0105"> <h6 class="title">Diabetes‐related complications</h6> <p>None of the included studies reported this outcome.</p> </section> <section id="CD011919-sec-0106"> <h6 class="title">Adverse events</h6> <p>All included studies reported that no adverse events were observed (very low‐certainty evidence). </p> </section> </section> <section id="CD011919-sec-0107"> <h5 class="title">Secondary outcomes</h5> <section id="CD011919-sec-0108"> <h6 class="title">Diabetes‐related mortality</h6> <p>No study was powered to investigate all‐cause mortality. However, study authors reported that no adverse events were observed, indicating that no deaths occurred (very low‐certainty evidence). </p> </section> <section id="CD011919-sec-0109"> <h6 class="title">Health‐related quality of life</h6> <p>None of the included studies reported this outcome.</p> </section> <section id="CD011919-sec-0110"> <h6 class="title">HbA1c</h6> <p>Two studies with a cross‐over design reported data on HbA1c for 31 participants with T2DM (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). Using individual participant data provided by study authors, we controlled for intraclass correlations and then calculated mean differences between the two intervention groups using a mixed analysis of variance (ANOVA) model. Resveratrol versus placebo showed neutral effects for HbA1c levels (mean difference (MD) 0.1%, 95% confidence interval (CI) ‐0.02 to 0.2); P = 0.09; 2 studies; 31 participants; very low‐certainty evidence; <a href="./references#CD011919-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD011919-sec-0111"> <h6 class="title">Fasting blood glucose</h6> <p>Two cross‐over studies reported data on fasting blood glucose (FBG) levels for 31 participants with T2DM (<a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). Using individual participant data provided by study authors, we controlled for intraclass correlations and then calculated mean differences between the two intervention groups using a mixed ANOVA model. Resveratrol versus placebo showed neutral effects for FBG levels (MD 2 mg/dL, 95% CI ‐2 to 7; P = 0.29; 2 studies; 31 participants; <a href="./references#CD011919-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD011919-sec-0112"> <h6 class="title">Insulin sensitivity</h6> <p>Two studies reported data on insulin sensitivity as measured by HOMA‐IR for 36 participants with type 2 diabetes mellitus (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>; <a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>). We obtained individual participant data from study authors for one cross‐over RCT (<a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a>), controlled for intraclass correlations, and calculated mean differences between the two intervention groups using a mixed ANOVA model. The second study used a parallel design (<a href="./references#CD011919-bbs2-0001" title="BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans. Diabetologia2010;53:S301. BrasnyóP , MolnárGA , MohásM , MarkóL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyó 2011</a>). Resveratrol versus placebo showed neutral effects for insulin resistance (MD ‐0.35, 95% CI ‐0.99 to 0.28; P = 0.27; 2 studies; 36 participants; <a href="./references#CD011919-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD011919-sec-0113"> <h6 class="title">Socioeconomic effects</h6> <p>None of the included studies reported this outcome.</p> </section> </section> </section> <section id="CD011919-sec-0114"> <h4 class="title">Subgroup analyses</h4> <p>We did not perform subgroup analyses because we found insufficient trials to estimate effects in various subgroups. </p> </section> <section id="CD011919-sec-0115"> <h4 class="title">Sensitivity analyses</h4> <p>We did not perform sensitivity analyses due to insufficient studies reporting our primary outcome. </p> </section> <section id="CD011919-sec-0116"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not generate funnel plots due to the limited number of included studies (N = 3). </p> </section> <section id="CD011919-sec-0117"> <h4 class="title">Ongoing trials</h4> <p>We found eight ongoing RCTs that fit the inclusion criteria of this review (<a href="./references#CD011919-bbs2-0032" title="CTRI/2017/04/008384 . A study to check whether addition of resveratrol is beneficial and safe in patients with diabetes, dyslipidemia and hypertension (who are already on standard therapy). www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=11073 (first received 20 April 2017). ">CTRI/2017/04/008384</a>; <a href="./references#CD011919-bbs2-0033" title="IRCT201411112394N14 . Effects of resveratrol on mood and cognition in patients with type 2 diabetes. en.irct.ir/trial/2084?revision=2084 (first received 18 August 2015). ">IRCT201411112394N14</a>; <a href="./references#CD011919-bbs2-0034" title="IRCT201601022394N19 . Effect of resveratrol on serum irisin and adiponectin in patients with type 2 diabetes. en.irct.ir/trial/2085 (first received 24 July 2016). ">IRCT201601022394N19</a>; <a href="./references#CD011919-bbs2-0035" title="IRCT20171118037528N1 . Effect of resveratrol on vascular function. en.irct.ir/trial/27734 (first received 29 December 2017). ">IRCT20171118037528N1</a>; <a href="./references#CD011919-bbs2-0036" title="NCT01158417 . Resveratrol in type2 diabetes and obesity. clinicaltrials.gov/show/NCT01158417 (first received 8 July 2010). ">NCT01158417</a>; <a href="./references#CD011919-bbs2-0037" title="NCT01881347 . Effects of resveratrol on endothelial function in type 2 diabetes mellitus. clinicaltrials.gov/show/NCT01881347 (first received 19 June 2013). ">NCT01881347</a>; <a href="./references#CD011919-bbs2-0038" title="NCT02549924 . Effect of administration of resveratrol on glycemic variability in individuals with type 2 diabetes mellitus. clinicaltrials.gov/show/NCT02549924 (first received 15 September 2015). ">NCT02549924</a>; <a href="./references#CD011919-bbs2-0039" title="SLCTR/2018/019 . Effects of delta‐tocotrienol, resveratrol and vitamin D supplementation mixture on biochemical markers in diabetic patients. slctr.lk/trials/1304 (first received 21 June 2018). ">SLCTR/2018/019</a>). Out of these eight ongoing trials, seven are of parallel design (<a href="./references#CD011919-bbs2-0032" title="CTRI/2017/04/008384 . A study to check whether addition of resveratrol is beneficial and safe in patients with diabetes, dyslipidemia and hypertension (who are already on standard therapy). www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=11073 (first received 20 April 2017). ">CTRI/2017/04/008384</a>; <a href="./references#CD011919-bbs2-0033" title="IRCT201411112394N14 . Effects of resveratrol on mood and cognition in patients with type 2 diabetes. en.irct.ir/trial/2084?revision=2084 (first received 18 August 2015). ">IRCT201411112394N14</a>; <a href="./references#CD011919-bbs2-0034" title="IRCT201601022394N19 . Effect of resveratrol on serum irisin and adiponectin in patients with type 2 diabetes. en.irct.ir/trial/2085 (first received 24 July 2016). ">IRCT201601022394N19</a>; <a href="./references#CD011919-bbs2-0035" title="IRCT20171118037528N1 . Effect of resveratrol on vascular function. en.irct.ir/trial/27734 (first received 29 December 2017). ">IRCT20171118037528N1</a>; <a href="./references#CD011919-bbs2-0036" title="NCT01158417 . Resveratrol in type2 diabetes and obesity. clinicaltrials.gov/show/NCT01158417 (first received 8 July 2010). ">NCT01158417</a>; <a href="./references#CD011919-bbs2-0038" title="NCT02549924 . Effect of administration of resveratrol on glycemic variability in individuals with type 2 diabetes mellitus. clinicaltrials.gov/show/NCT02549924 (first received 15 September 2015). ">NCT02549924</a>; <a href="./references#CD011919-bbs2-0039" title="SLCTR/2018/019 . Effects of delta‐tocotrienol, resveratrol and vitamin D supplementation mixture on biochemical markers in diabetic patients. slctr.lk/trials/1304 (first received 21 June 2018). ">SLCTR/2018/019</a>), and one is a cross‐over trial (<a href="./references#CD011919-bbs2-0037" title="NCT01881347 . Effects of resveratrol on endothelial function in type 2 diabetes mellitus. clinicaltrials.gov/show/NCT01881347 (first received 19 June 2013). ">NCT01881347</a>). The approximate number of participants in these eight ongoing trials is 800. </p> <p>Furthermore, we identified two studies that are awaiting assessment, which could possibly contribute to the findings of our systematic review (<a href="./references#CD011919-bbs2-0030" title="ACTRN12614000891628 . Dose response evaluation of resveratrol supplementation on cerebrovascular function, mood and cognitive performance in type 2 diabetes mellitus (T2DM). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366701 (first received 12 August 2014). WongRH , NealonRS , ScholeyA , HowePR . Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus. Nutrition, Metabolism, and Cardiovascular Diseases2016;26(5):393‐9. WongRH , RaederstorffD , HowePR . Acute resveratrol consumption improves neurovascular coupling capacity in adults with type 2 diabetes mellitus. Nutrients2016;8(7):425. ">ACTRN12614000891628</a>; <a href="./references#CD011919-bbs2-0031" title="VergesB , BrindisiMC , BouilletB , CrevisyE , BuffierP , Baillot‐RudoniS , et al. Is long‐acting resveratrol effective on the residual dyslipidemia in statin‐treated type 2 diabetic patients?. Atherosclerosis2014;235(2014):e192. ">Verges 2014</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011919-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011919-sec-0118"></div> <section id="CD011919-sec-0119"> <h3 class="title" id="CD011919-sec-0119">Summary of main results</h3> <p>In this systematic review, we sought to identify the efficacy and safety of resveratrol in the treatment of adults with type 2 diabetes mellitus (T2DM). Using a comprehensive search strategy and an independent duplicate study selection process, we identified three randomised controlled trials (RCTs) (one parallel‐design RCT and two cross‐over design RCTs) with 50 adult participants with T2DM that fit our inclusion criteria. All three studies administered different doses of oral resveratrol as their intervention, and all used placebo as a comparator. None of our patient‐relevant outcomes such as all‐cause mortality, diabetes‐related complications, diabetes‐related mortality, socioeconomic effects, and health‐related quality of life were reported by the included studies. Instead, surrogate outcomes such as glycosylated haemoglobin A1c (HbA1c), fasting blood glucose (FBG), and insulin sensitivity were reported. Results for the outcomes HbA1c, FBG, and insulin resistance showed neutral effects. </p> <p>Based on current limited evidence, resveratrol seems to be well tolerated, with none of the study participants reporting adverse events. Although this systematic review offers up‐to‐date evidence on the efficacy of resveratrol for adults with T2DM, this evidence is very limited, as it is supported by only a few small RCTs reporting surrogate outcomes. Another limitation is that the follow‐up periods in these studies were very short (follow‐up periods ranged from four weeks to five weeks), and the long‐term effects of resveratrol remain unclear. Thus, evidence is currently insufficient to support the use of resveratrol supplementation in adults for treatment of T2DM. </p> </section> <section id="CD011919-sec-0120"> <h3 class="title" id="CD011919-sec-0120">Overall completeness and applicability of evidence</h3> <p>The main objective of this systematic review was to investigate the safety and efficacy of resveratrol in adults with T2DM. The three studies included in this review reported a few of our predefined primary and secondary outcome measures. Some of our patient‐important primary outcomes such as all‐cause mortality, diabetes‐related mortality, and diabetes‐related complications were not reported by any of the included studies. The one‐month measurements of HbA1c reported in the included studies were too short for this outcome to be considered reliable. Also, variation in the dose of resveratrol reported in the included studies (10 mg/d to 1000 mg/d) was too wide to allow any meaningful conclusions regarding the effective dose of resveratrol. Lack of studies reporting outcomes, use of different doses and varying duration of intervention among studies, and lack of long‐term follow‐up made comparisons among the included studies very difficult. The body of evidence on resveratrol for treatment of adults with T2DM is very limited. With limited evidence available from a few small studies, resveratrol appears to be generally safe with the potential for beneficial effects on insulin resistance in people with T2DM. But no firm conclusions can be reached. Future studies with longer follow‐up periods are needed to investigate the impact of resveratrol on T2DM. </p> </section> <section id="CD011919-sec-0121"> <h3 class="title" id="CD011919-sec-0121">Quality of the evidence</h3> <p>The certainty of evidence was adjudicated according to the GRADE approach for all key patient‐important outcomes. The seven patient‐important outcomes for which we evaluated the strength of evidence were adverse events, all‐cause mortality, diabetes‐related mortality, diabetes‐related complications, HbA1c, health‐related quality of life, and socioeconomic effects. Due to the small number of studies reporting, small sample sizes, and short‐term follow‐up, we judged all reported outcomes to provide very low‐certainty evidence. Thus we can place only low confidence in our effect estimates. Funnel plot asymmetry was not tested as included studies were too few. </p> </section> <section id="CD011919-sec-0122"> <h3 class="title" id="CD011919-sec-0122">Potential biases in the review process</h3> <p>We followed the methods listed in the protocol and made no post‐hoc decisions. We made an attempt to contact all authors of included studies for specific information regarding available outcome data. Only a few study authors responded, and this could have limited the availability and analysis of missing outcomes from these studies. Although we did a comprehensive database search for this review without limitations on language of publication, unpublished studies (English and non‐English) could have been missed, leading to the possibility of publication and language bias. </p> </section> <section id="CD011919-sec-0123"> <h3 class="title" id="CD011919-sec-0123">Agreements and disagreements with other studies or reviews</h3> <p>Three systematic reviews have reported the effects of resveratrol on individuals with T2DM (<a href="./references#CD011919-bbs2-0062" title="HausenblasHA , SchouldaJA , SmoligaJM . Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus ‐ systematic review and meta‐analysis. Molecular Nutrition &amp; Food Research2015;59(1):147‐59. ">Hausenblas 2015</a>; <a href="./references#CD011919-bbs2-0075" title="LiuK , ZhouR , WangB , MiMT . Effect of resveratrol on glucose control and insulin sensitivity: a meta‐analysis of 11 randomized controlled trials. American Journal of Clinical Nutrition2014;99(6):1510‐9. ">Liu 2014</a>; <a href="./references#CD011919-bbs2-0095" title="ZhuX , WuC , QiuS , YuanX , LiL . Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta‐analysis. Nutrition and Metabolism2017;14:60. ">Zhu 2017</a>). The first systematic review published the effects of resveratrol as an adjunct treatment to pharmaceutical interventions for T2DM on cardio‐metabolic biomarkers (<a href="./references#CD011919-bbs2-0062" title="HausenblasHA , SchouldaJA , SmoligaJM . Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus ‐ systematic review and meta‐analysis. Molecular Nutrition &amp; Food Research2015;59(1):147‐59. ">Hausenblas 2015</a>). The second and the third systematic reviews published the effects of resveratrol in participants with and without T2DM on glucose control and insulin sensitivity (<a href="./references#CD011919-bbs2-0075" title="LiuK , ZhouR , WangB , MiMT . Effect of resveratrol on glucose control and insulin sensitivity: a meta‐analysis of 11 randomized controlled trials. American Journal of Clinical Nutrition2014;99(6):1510‐9. ">Liu 2014</a>; <a href="./references#CD011919-bbs2-0095" title="ZhuX , WuC , QiuS , YuanX , LiL . Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta‐analysis. Nutrition and Metabolism2017;14:60. ">Zhu 2017</a>). These three systematic reviews reported positive effects of resveratrol on some but not all cardio‐metabolic markers, and they did not assess the effects of resveratrol on key patient‐important outcomes such as all‐cause mortality, diabetes‐related mortality, diabetes‐related complications, and health‐related quality of life that we have addressed in our review. Although surrogate outcomes provide useful information, it is very important to investigate patient‐important endpoints that are directly meaningful to individuals with T2DM. It is important to note that in these three systematic reviews, the review authors included a broad mixture of interventions (resveratrol plus various additional compounds), making it impossible to reliably delineate the effects of resveratrol only. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011919-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/urn:x-wiley:14651858:media:CD011919:CD011919-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_t/tCD011919-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011919-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011919-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/urn:x-wiley:14651858:media:CD011919:CD011919-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_t/tCD011919-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not measured in some studies)." data-id="CD011919-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not measured in some studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011919-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/urn:x-wiley:14651858:media:CD011919:CD011919-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_t/tCD011919-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not measure that particular outcome)." data-id="CD011919-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not measure that particular outcome). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011919-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/urn:x-wiley:14651858:media:CD011919:CD011919-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_t/tCD011919-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resveratrol versus placebo, Outcome 1 HbA1c [%]." data-id="CD011919-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Resveratrol versus placebo, Outcome 1 HbA1c [%].</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/references#CD011919-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011919-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/urn:x-wiley:14651858:media:CD011919:CD011919-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_t/tCD011919-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resveratrol versus placebo, Outcome 2 FBG [mg/dL]." data-id="CD011919-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Resveratrol versus placebo, Outcome 2 FBG [mg/dL].</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/references#CD011919-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011919-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/urn:x-wiley:14651858:media:CD011919:CD011919-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_t/tCD011919-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resveratrol versus placebo, Outcome 3 Insulin sensitivity (measured by HOMA‐IR)." data-id="CD011919-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Resveratrol versus placebo, Outcome 3 Insulin sensitivity (measured by HOMA‐IR). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/references#CD011919-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/media/CDSR/CD011919/image_n/nCD011919-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011919-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for resveratrol plus oral anti‐diabetic drugs versus placebo plus oral anti‐diabetic drugs</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Resveratrol compared with placebo for type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> adults with type 2 diabetes mellitus<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> resveratrol + OAD<br/> <b>Comparison:</b> placebo + OAD </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo + OAD</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with resveratrol + OAD</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes‐related complications</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 4 to 5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Very low</b><sup>a</sup> </p> <p>⊕⊕⊝⊝</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events were reported, indicating that no deaths occurred</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes‐related mortality</b> </p> <p>Follow‐up: 4 to 5 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Very low</b><sup>a</sup> </p> <p>⊕⊕⊝⊝</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events were reported, indicating that no deaths occurred</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 4 to 5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>a</sup> </p> <p>⊕⊕⊝⊝</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse events were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c (%)</b> </p> <p>Follow‐up: 30 days and 5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean HbA1c in the intervention group was 0.1% higher (0.02% lower to 0.2% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b</sup> </p> <p>⊕⊕⊝⊝</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to the short follow‐up period, HbA1c results have to be interpreted cautiously</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; HbA1c: glycosylated haemoglobin A1c; OAD: oral anti‐diabetic drug(s). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level because of indirectness (insufficient time frame) and by two levels because of serious imprecision (low median sample size and small number of studies) ‐ see <a href="./appendices#CD011919-sec-0143">Appendix 14</a>.<br/> <sup>b</sup>Downgraded by one level because of indirectness (surrogate outcome and insufficient time frame) and by two levels because of serious imprecision (low median sample size and small number of studies, CI ranging between benefit and harm) ‐ see <a href="./appendices#CD011919-sec-0143">Appendix 14</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for resveratrol plus oral anti‐diabetic drugs versus placebo plus oral anti‐diabetic drugs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011919-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of study populations</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID<br/> (study design)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing study<br/> (N)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing study<br/> (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011919-bbs2-0003" title="NCT01638780 . Resveratrol and type 2 diabetes. clinicaltrials.gov/show/NCT01638780 (first received 12 July 2012). TimmersS , deLigtM , PhielixE , van deWeijerT , HansenJ , Moonen‐KornipsE , et al. Resveratrol as add‐on therapy in subjects with well‐controlled type 2 diabetes: a randomized controlled trial. Diabetes Care2016;39(12):2211‐7. ">Timmers 2016</a> </p> <p>(cross‐over RCT, 30‐day washout period)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: trans‐resveratrol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"We estimated 14 subjects were required to achieve 80% power, with an assumed treatment difference of 1.4 mg/kg fat‐free mass/min after 30 days and an assumed SD of 1.7 mg/kg fat‐free mass/min for a hyperinsulinaemic clamp. A dropout of 20% was taken into account, so 17 subjects were recruited" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>30 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011919-bbs2-0002" title="ACTRN12613000717752 . The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364511 (first received 1 June 2013). ThazhathSS , WuT , BoundMJ , ChecklinHL , StandfieldS , JonesKL , et al. Administration of resveratrol for 5 weeks has no effect on glucagon‐like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. American Journal of Clinical Nutrition2016; Vol. 103:66‐70. ">Thazhath 2016</a> </p> <p>(cross‐over RCT, 5‐week washout period)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: resveratrol capsule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A sample size of 14 subjects would have 80% power (at alpha = 0.05) to detect a 50% difference in the postprandial AUC for plasma total GLP‐1, which was the primary endpoint" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>5 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011919-bbs2-0051" title="BrasnyoP , MolnarGA , MohasM , MarkoL , LaczyB , CsehJ , et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the akt pathway in type 2 diabetic patients. British Journal of Nutrition2011;106:383‐9. ">Brasnyo 2011</a> </p> <p>(parallel RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: resveratrol capsule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Grand total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All comparators</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions and comparators</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>81</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>81</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>— denotes not reported.</p> <p><sup>a</sup>Cross‐over study: each participant received both placebo and resveratrol; total number of participants was 50.<br/> AUC: area under the curve. </p> <p>C: comparator, GLP‐1: glucagon‐like peptide‐1, I: intervention, RCT: randomised controlled trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of study populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/full#CD011919-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011919-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Resveratrol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 HbA1c [%] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.02, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 FBG [mg/dL] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [‐2.10, 6.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Insulin sensitivity (measured by HOMA‐IR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.99, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Resveratrol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011919.pub2/references#CD011919-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011919.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011919-note-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011919-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011919-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011919-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD011919-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011919-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011919-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011919-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011919-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011919-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011919\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011919\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011919\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011919\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011919\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011919.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011919.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011919.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011919.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011919.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717167147"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011919.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717167151"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011919.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db1502c9e936e',t:'MTc0MDcxNzE2Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 